[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Bone marrow,Leukemias,Natural killer cells,Regulatory T cells,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. D. Bui<\/b><sup>1<\/sup>, C. Lee<sup>1<\/sup>, C. Caron<sup>1<\/sup>, D. Lee<sup>2<\/sup>, Z. DeFilipp<sup>3<\/sup>, Y.-B. Chen<sup>3<\/sup>; <br\/><sup>1<\/sup>UC San Diego, La Jolla, CA, <sup>2<\/sup>Medical Affairs, San Diego, CA, <sup>3<\/sup>Massachusetts General Hospital, Boston, MA","CSlideId":"","ControlKey":"bad7a298-5bb2-4c3c-a697-216da8663e97","ControlNumber":"10827","DisclosureBlock":"<b>&nbsp;J. D. Bui, <\/b> <br><b>REGiMMUNE<\/b> Grant\/Contract. <br><b>Paramita Therapeutics<\/b> Stock. <br><b>Pathfinder<\/b> Stock. <br><b>Neuvogen<\/b> Stock Option. <br><b>C. Lee, <\/b> <br><b>Pfizer<\/b> Employment.<br><b>C. Caron, <\/b> None.&nbsp;<br><b>D. Lee, <\/b> <br><b>Medical Affairs<\/b> Employment. <br><b>REGiMMUNE<\/b> Independent Contractor.<br><b>Z. DeFilipp, <\/b> None..<br><b>Y. Chen, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11563","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT242","PresenterBiography":null,"PresenterDisplayName":"Jack Bui, MD;PhD","PresenterKey":"f3ea06ee-08e5-43bb-a0cf-a8205f80dd0e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT242. Phase 2b study of alloHSCT patients receiving RGI-2001, an NKT cell activator, demonstrates safety and protection from acute GVHD, correlating with increased NKT cell number in patient blood.","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 2b study of alloHSCT patients receiving RGI-2001, an NKT cell activator, demonstrates safety and protection from acute GVHD, correlating with increased NKT cell number in patient blood.","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Non-Hodgkin's lymphoma,Bispecific antibody therapy,indolent lymphoma,Phase 2,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. Chong<\/b><sup>1<\/sup>, M. Taszner<sup>2<\/sup>, S. Novelli<sup>3<\/sup>, S.-G. Cho<sup>4<\/sup>, J. C. Villasboas<sup>5<\/sup>, A. Ubieto<sup>6<\/sup>, B. Tessoulin<sup>7<\/sup>, M. Poon<sup>8<\/sup>, D. Tucker<sup>9<\/sup>, J. Walewski<sup>10<\/sup>, Y. Song<sup>11<\/sup>, E. Bachy<sup>12<\/sup>, S. Guidez<sup>13<\/sup>, A. Alonso<sup>14<\/sup>, D. Jagadeesh<sup>15<\/sup>, S. Luminari<sup>16<\/sup>, L. Mayer<sup>17<\/sup>, E. Iskierka-Ja&#380;d&#380;ewska<sup>18<\/sup>, M. Tani<sup>19<\/sup>, J. Cai<sup>20<\/sup>, A. Uppala<sup>20<\/sup>, S. Shariff<sup>21<\/sup>, J. Brouwer-Visser<sup>20<\/sup>, A. Chaudhry<sup>20<\/sup>, H. Mohamed<sup>20<\/sup>, S. Ambati<sup>20<\/sup>, T. Kim<sup>22<\/sup>; <br\/><sup>1<\/sup>Olivia Newton-John Cancer Centre, Heidelberg, Australia, <sup>2<\/sup>Medical University of Gda&#324;sk, Gda&#324;sk, Poland, <sup>3<\/sup>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, <sup>4<\/sup>Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of, <sup>5<\/sup>Mayo Clinic, Rochester, MN, <sup>6<\/sup>Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>7<\/sup>Nantes University Hospital, Nantes, France, <sup>8<\/sup>National University Hospital, Singapore, Singapore, <sup>9<\/sup>Royal Cornwall Hospital, Truro, United Kingdom, <sup>10<\/sup>Narodowy Instytut Onkologii im. Marii Sk&#322;odowskiej-Curie Pa&#324;stwowy Instytut Badawczy, Warsawa, Poland, <sup>11<\/sup>Peking University Cancer Hospital and Institute, Beijing, China, <sup>12<\/sup>Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France, <sup>13<\/sup>Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers, France, <sup>14<\/sup>Hospital Universitario Quiron Salud Madrid, Madrid, Spain, <sup>15<\/sup>Cleveland Clinic Main Campus, Cleveland, OH, <sup>16<\/sup>Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy, <sup>17<\/sup>Hospital Clínic de Barcelona, Barcelona, Spain, <sup>18<\/sup>Copernicus Memorial Hospital, Medical University of &#321;ód&#378;, &#321;ód&#378;, Poland, <sup>19<\/sup>Hospital Santa Maria delle Croci Hospital, Ravenna, Italy, <sup>20<\/sup>Regeneron Pharmaceuticals, Inc., Tarrytown, NY, <sup>21<\/sup>Regeneron UK Ltd., Uxbridge, United Kingdom, <sup>22<\/sup>Seoul National University Hospital, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"d1f3e619-ca75-4875-905c-0c5e35531867","ControlNumber":"10672","DisclosureBlock":"<b>&nbsp;G. Chong, <\/b> <br><b>Regeneron Pharmaceuticals Inc.<\/b> Other, Research or Clinical Trial Funding. <br><b>Pharmacyclics<\/b> Other, Research or Clinical Trial Funding. <br><b>Merck Serono<\/b> Other, Research or Clinical Trial Funding. <br><b>AstraZeneca<\/b> Other, Research or Clinical Trial Funding. <br><b>Bayer<\/b> Other, Research or Clinical Trial Funding. <br><b>HUTCHMED<\/b> Other, Research or Clinical Trial Funding. <br><b>Bristol Myers Squibb<\/b> Other, Research or Clinical Trial Funding and membership on an entity's Board of Directors or advisory committees. <br><b>Incyte<\/b> Other, Research or Clinical Trial Funding. <br><b>MorphoSys<\/b> Other, Research or Clinical Trial Funding. <br><b>Isofol<\/b> Other, Research or Clinical Trial Funding. <br><b>Seagen<\/b> Research or Clinical Trial Funding. <br><b>Amgen<\/b> Other, Research or Clinical Trial Funding. <br><b>Takeda<\/b> Other, Membership on an entity's Board of Directors or advisory committees. <br><b>Dizal Pharma<\/b> Research or Clinical Trial Funding. <br><b>M. Taszner, <\/b> <br><b>Roche<\/b> Other, Consultancy. <br><b>Takeda<\/b> Other, Consultancy. <br><b>S. Novelli, <\/b> <br><b>Mundipharma<\/b> Other, Consultancy. <br><b>Novartis<\/b> Other, Research Funding. <br><b>S. Cho, <\/b> <br><b>LucasBio<\/b> Stock, Stock Option. <br><b>VigenCell<\/b> Stock, Stock Option. <br><b>J. C. Villasboas, <\/b> <br><b>Regeneron Pharmaceuticals Inc.<\/b> Other, Research Funding and Consultancy and\/or Advisory Role. <br><b>Aptose Biosciences<\/b> Other, Research Funding. <br><b>Epizyme<\/b> Other, Research Funding. <br><b>Enterome<\/b> Other, Research Funding. <br><b>Kite\/Gilead<\/b> Other, Consultancy\/Advisory Role. <br><b>Genentech<\/b> Other, Research Funding. <br><b>Curio Science<\/b> Other, Consultancy and\/or advisory role. <br><b>TG Therapeutics<\/b> Other, Consultancy and\/or advisory role.<br><b>A. Ubieto, <\/b> None.&nbsp;<br><b>B. Tessoulin, <\/b> <br><b>AbbVie<\/b> Other, Honoraria and Travel\/accommodation\/other expenses. <br><b>Gilead<\/b> Other, Honoraria and Travel\/accommodation\/other expenses. <br><b>Kite<\/b> Other, Honoraria and Travel\/accommodation\/other expenses.<br><b>M. Poon, <\/b> None.&nbsp;<br><b>D. Tucker, <\/b> <br><b>Regeneron Pharmaceuticals Inc.<\/b> Other, Consultancy. <br><b>AbbVie<\/b> Other, Consultancy. <br><b>BeiGene<\/b> Other, Consultancy and Travel\/accommodation\/other expenses. <br><b>Immunovant<\/b> Other, Consultancy. <br><b>Gilead<\/b> Other, Consultancy Role. <br><b>J. Walewski, <\/b> <br><b>AbbVie<\/b> Other, Consultancy and Honoraria. <br><b>Gilead<\/b> Other, Consultancy, Research or clinical trial funding and Honoraria. <br><b>Novartis<\/b> Other, Consultancy, Research or Clinical Trial funding and honoraria. <br><b>Roche<\/b> Other, Consultancy, Research or Clinical Trial funding and honoraria. <br><b>Takeda<\/b> Other, Consultancy and Research or clinical trial funding. <br><b>GSK<\/b> Other, Research or Clinical Trial funding. <br><b>Amgen<\/b> Other, Honoraria. <br><b>Astra Zeneca\/MedImmune<\/b> Other, Research or clinical trial funding. <br><b>BMS<\/b> Other, Research or clinical trial funding. <br><b>Epizyme<\/b> Other, Research or clinical trial funding. <br><b>Incyte<\/b> Other, Research or clinical trial funding. <br><b>Janssen<\/b> Other, Research or clinical trial funding. <br><b>Karyopharm Therapeutics<\/b> Other, Research or clinical trial funding. <br><b>Loxo\/Lilly<\/b> Other, Research or clinical trial funding. <br><b>MorphoSys<\/b> Other, Research or clinical trial funding. <br><b>MSD Oncology<\/b> Other, Research or clinical trial funding. <br><b>NanoVector<\/b> Other, Research or clinical trial funding. <br><b>Regeneron<\/b> Other, Research or clinical trial funding. <br><b>Seattle Genetics<\/b> Research or clinical trial funding. <br><b>TG Therapeutics & Vanda Pharmaceuticals<\/b> Other, Research or clinical trial funding.<br><b>Y. Song, <\/b> None.&nbsp;<br><b>E. Bachy, <\/b> <br><b>Amgen<\/b> Other, Research or Clinical trial funding. <br><b>BMS<\/b> Other, Research or Clinical trial funding, Honoraria and other (personal) fees. <br><b>Kite\/Gilead<\/b> Other, Honoraria and other (personal) fees. <br><b>Incyte<\/b> Other, Honoraria. <br><b>Novartis<\/b> Other, Honoraria and other (personal) fees. <br><b>Pfizer<\/b> Other, Honoraria and other (personal) fees. <br><b>Roche<\/b> Other, Honoraria and Consultancy. <br><b>Takeda<\/b> Other, Honoraria. <br><b>S. Guidez, <\/b> <br><b>Kite\/Gilead<\/b> Other, Honoraria.<br><b>A. Alonso, <\/b> None.&nbsp;<br><b>D. Jagadeesh, <\/b> <br><b>Atara Biotherapeutics<\/b> Other, Research funding. <br><b>AstraZeneca<\/b> Other, Research funding. <br><b>Debiopharm<\/b> Other, Research funding. <br><b>Loxo Oncology<\/b> Other, Research funding. <br><b>MEI Pharma<\/b> Other, Research funding. <br><b>Regeneron Pharmaceuticals Inc.<\/b> Other, Research funding. <br><b>Seagen<\/b> Other, Research funding. <br><b>Trillium Therapeutics<\/b> Other, Research funding. <br><b>Affimed<\/b> Other, Membership of advisory committee. <br><b>Daiichi Sankyo<\/b> Other, Membership of advisory committee. <br><b>S. Luminari, <\/b> <br><b>Roche<\/b> Other, Membership on an entity's Board of Directors or advisory committee. <br><b>Janssen<\/b> Other, Membership on an entity's Board of Directors or advisory committee. <br><b>BeiGene<\/b> Other, Membership on an entity's Board of Directors or advisory committee. <br><b>Regeneron Pharmaceuticals Inc.<\/b> Other, Membership on an entity's Board of Directors or advisory committee. <br><b>Kite<\/b> Other, Membership on an entity's Board of Directors or advisory committee. <br><b>BMS<\/b> Other, Membership on an entity's Board of Directors or advisory committee. <br><b>AbbVie<\/b> Other, Membership on an entity's Board of Directors or advisory committee.<br><b>L. Mayer, <\/b> None.&nbsp;<br><b>E. Iskierka-Ja&#380;d&#380;ewska, <\/b> <br><b>AbbVie<\/b> Other, Consultancy and honoraria. <br><b>AstraZeneca<\/b> Other, Consultancy and honoraria. <br><b>Janssen<\/b> Other, Honoraria. <br><b>Novartis<\/b> Other, Honoraria. <br><b>M. Tani, <\/b> <br><b>AbbVie<\/b> Reports membership of advisory committees. <br><b>Jansen-Cliag<\/b> Reports membership of advisory committees. <br><b>Incyte<\/b> Reports membership of advisory committees. <br><b>J. Cai, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option. <br><b>A. Uppala, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option. <br><b>S. Shariff, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option. <br><b>J. Brouwer-Visser, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option. <br><b>A. Chaudhry, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option. <br><b>H. Mohamed, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option. <br><b>S. Ambati, <\/b> <br><b>Regeneron Pharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option. <br><b>T. Kim, <\/b> <br><b>Amgen<\/b> Other, Consultancy and\/or an Advisory role and received trial research funding (to institution). <br><b>AstraZeneca\/MedImmune<\/b> Other, Consultancy and\/or an Advisory role and received trial research funding (to institution). <br><b>Daiichi Sankyo<\/b> Other, Consultancy and\/or an Advisory role. <br><b>Janssen<\/b> Other, Consultancy and\/or an Advisory role. <br><b>HK Inno.N<\/b> Other, Consultancy\/Advisory role. <br><b>Novartis<\/b> Other, Consultancy and\/or an Advisory role. <br><b>Regeneron Pharmaceuticals Inc.<\/b> Other, Consultancy and\/or an Advisory role. <br><b>Samsung Bioepis<\/b> Other, Consultancy and\/or an Advisory role. <br><b>Takeda<\/b> Other, Consultancy and\/or an Advisory role and received trial research funding (to institution). <br><b>Yuhan<\/b> Other, Consultancy and\/or an Advisory role. <br><b>IMB DX<\/b> Other, Speaker's Bureau. <br><b>Janssen<\/b> Other, Speaker's Bureau. <br><b>Takeda<\/b> Other, Speaker's Bureau.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11564","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT243","PresenterBiography":null,"PresenterDisplayName":"Geoffrey Chong, MD","PresenterKey":"657c973d-1396-4ac5-ab6b-80a4c8a64a80","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT243. Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed\/refractory follicular lymphoma (R\/R FL)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed\/refractory follicular lymphoma (R\/R FL)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"CAR T cells,Adverse effects,Survival,Response,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Zhang<sup>1<\/sup>, Y. Li<sup>2<\/sup>, K. Hu<sup>3<\/sup>, W. Li<sup>4<\/sup>, H. Xue<sup>5<\/sup>, Q. Deng<sup>6<\/sup>, Z. Ge<sup>7<\/sup>, L. Geng<sup>8<\/sup>, X. Song<sup>9<\/sup>, K. Yu<sup>10<\/sup>, H. Jing<sup>11<\/sup>, B. Chen<sup>12<\/sup>, X. Li<sup>13<\/sup>, Z. Zhai<sup>14<\/sup>, J. Shen<sup>15<\/sup>, J. Cao<sup>16<\/sup>, Q. Wang<sup>17<\/sup>, <b>P. Liu<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Zhongshan Hospital Fudan University, Shanghai, China, <sup>2<\/sup>Zhujiang Hospital, Southern Medical University, Guangzhou, China, <sup>3<\/sup>Beijing Boren Hospital, Beijing, China, <sup>4<\/sup>Jiangxi Cancer Hospital, Nanchang, China, <sup>5<\/sup>The Affiliated Hospital of Qingdao University, Qingdao, China, <sup>6<\/sup>Tianjin First Central Hospital, Nankai University, Tianjin, China, <sup>7<\/sup>Zhongda Hospital, Southeast University, Nanjing, China, <sup>8<\/sup>Anhui Provincial Hospital, Hefei, Hefei, China, <sup>9<\/sup>Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, <sup>10<\/sup>The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, <sup>11<\/sup>Peking University Third Hospital, Beijing, China, <sup>12<\/sup>Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China, <sup>13<\/sup>The Third Xiangya Hospital of Central South University, Changsha, China, <sup>14<\/sup>The Second Affiliated Hospital of Anhui Medical University, Anhui, China, <sup>15<\/sup>First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China, <sup>16<\/sup>The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, <sup>17<\/sup>The Second Affiliated Hospital of Nanchang University, Nanchang, China","CSlideId":"","ControlKey":"dc2c099d-0642-4b6c-b4d3-996b699b32f9","ControlNumber":"9716","DisclosureBlock":"&nbsp;<b>Y. Zhang, <\/b> None..<br><b>Y. Li, <\/b> None..<br><b>K. Hu, <\/b> None..<br><b>W. Li, <\/b> None..<br><b>H. Xue, <\/b> None..<br><b>Q. Deng, <\/b> None..<br><b>Z. Ge, <\/b> None..<br><b>L. Geng, <\/b> None..<br><b>X. Song, <\/b> None..<br><b>K. Yu, <\/b> None..<br><b>H. Jing, <\/b> None..<br><b>B. Chen, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>Z. Zhai, <\/b> None..<br><b>J. Shen, <\/b> None..<br><b>J. Cao, <\/b> None..<br><b>Q. Wang, <\/b> None..<br><b>P. Liu, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11565","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT244","PresenterBiography":null,"PresenterDisplayName":"Peng Liu, MD;PhD","PresenterKey":"a29b8aa5-00db-43b0-b131-ff22f255c330","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT244. HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory non-Hodgkin's lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory non-Hodgkin's lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Diffuse large B-cell lymphoma,Molecular markers,Checkpoint Inhibitors,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Shazia Nakhoda<sup>1<\/sup>, Tamarrah Sklarz<sup>1<\/sup>, Cheyenne Pagan<sup>1<\/sup>, Matthew Matasar<sup>2<\/sup>, Zachary  A.   K.  Frosch<sup>1<\/sup>, Marcus Messmer<sup>1<\/sup>, Asya Varshavsky Yanovsky<sup>1<\/sup>, Rashmi Khanal<sup>1<\/sup>, Carlyn Tan<sup>3<\/sup>, Eli Mikkelsen<sup>1<\/sup>, Henry Fung<sup>1<\/sup>, Eric Ross<sup>1<\/sup>, Mark Roschewski<sup>4<\/sup>, Allison Jacob<sup>1<\/sup>, <b>Nadia Khan<\/b><sup>5<\/sup><br><br\/><sup>1<\/sup>Fox Chase Cancer Center, Philadelphia, PA,<sup>2<\/sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,<sup>3<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY,<sup>4<\/sup>National Institute of Health, Bethesda, MD,<sup>5<\/sup>Swedish Cancer Institute, Seattle, WA","CSlideId":"","ControlKey":"ba594ea4-2a01-430a-a667-e8b386a78f39","ControlNumber":"9781","DisclosureBlock":"<b>&nbsp;S. Nakhoda, <\/b> <br><b>Bristol Myers Squibb<\/b> Advisory Board. <br><b>Astra Zeneca<\/b> Advisory Board. <br><b>ADC Therapeutics<\/b> Advisory Board. <br><b>BTG\/SERB<\/b> Advisory Board. <br><b>Beigene<\/b> Advisory Board.<br><b>T. Sklarz, <\/b> None..<br><b>C. Pagan, <\/b> None.&nbsp;<br><b>M. Matasar, <\/b> <br><b>Merck<\/b> Equity Holder. <br><b>Seagen<\/b> Other, Honoraria. <br><b>Hoffmann-La Roche Ltd<\/b> Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. <br><b>Genentech<\/b> Other, Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. <br><b>AstraZeneca<\/b> Other, Honoraria. <br><b>ADC Therapeutics<\/b> Other, Consultancy, Honoraria. <br><b>Teva<\/b> Other, Concsultancy. <br><b>Janssen<\/b> Honoraria, Research Funding. <br><b>Takeda<\/b> Other, Consultancy, Honoraria. <br><b>Immunovaccine Technologies<\/b> Other, Research Funding. <br><b>Seattle Genetics<\/b> Other, Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. <br><b>Pharmacyclics<\/b> Other, Honoraria, Research Funding. <br><b>Juno<\/b> Other, Consultancy. <br><b>Regeneron<\/b> Other, Honoraria. <br><b>Kite<\/b> Other, Honoraria. <br><b>Celgene<\/b> Other, Honoraria. <br><b>Bayer<\/b> Other, Consultancy, Honoraria, Research Funding. <br><b>Immunovaccine Technologies<\/b> Honoraria. <br><b>Bristol Myers Squibb<\/b> Other, Honoraria. <br><b>Z. A. K. Frosch, <\/b> <br><b>Seagen<\/b> Advisory Board. <br><b>Astra Zeneca<\/b> Other, Research Funding. <br><b>Abbvie<\/b> Other, Research Funding. <br><b>Roche<\/b> Research Funding.<br><b>M. Messmer, <\/b> None.&nbsp;<br><b>A. Varshavsky Yanovsky, <\/b> <br><b>Bristol Myers squibb<\/b> Other, Advisory Board. <br><b>Janssen<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Consulting.<br><b>R. Khanal, <\/b> None.&nbsp;<br><b>C. Tan, <\/b> <br><b>Takeda<\/b> Other, Research Funding. <br><b>Janssen<\/b> Research Funding.<br><b>E. Mikkelsen, <\/b> None..<br><b>H. Fung, <\/b> None..<br><b>E. Ross, <\/b> None..<br><b>M. Roschewski, <\/b> None.&nbsp;<br><b>A. Jacob, <\/b> <br><b>Adaptive Biotechnologies<\/b> Other, Current Employment, Current equity holder in publicly-traded company. <br><b>N. Khan, <\/b> <br><b>Abbvie; Adaptive\/Sequenta; Astra Zeneca; BeiGene<\/b> Other, Consultant.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11566","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT245","PresenterBiography":null,"PresenterDisplayName":"Nadia Khan, MD","PresenterKey":"c1a9facf-2f2f-4794-8b83-88b5ae438908","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT245. Circulating tumor DNA and nivolumab maintenance: A pilot study in diffuse large B cell lymphoma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Circulating tumor DNA and nivolumab maintenance: A pilot study in diffuse large B cell lymphoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,KRAS,Small molecule inhibitor,Targeted therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Z. Li<\/b><sup>1<\/sup>, X. Dang<sup>2<\/sup>, D. Huang<sup>3<\/sup>, S. Jin<sup>4<\/sup>, W. Li<sup>5<\/sup>, J. Shi<sup>6<\/sup>, X. Wang<sup>7<\/sup>, Y. Zhang<sup>8<\/sup>, Z. Song<sup>8<\/sup>, J. Zhang<sup>9<\/sup>, W. Zhuang<sup>10<\/sup>, X. Liu<sup>11<\/sup>, L. Jiang<sup>1<\/sup>, X. Meng<sup>12<\/sup>, M. Zhao<sup>13<\/sup>, J. Zhou<sup>14<\/sup>, L. Zhang<sup>15<\/sup>, P. Wang<sup>16<\/sup>, H. Luo<sup>17<\/sup>, J. Yang<sup>18<\/sup>, S. Cang<sup>19<\/sup>, X. Wang<sup>20<\/sup>, J. Wang<sup>21<\/sup>, J. Cui<sup>22<\/sup>, Y. Yu<sup>23<\/sup>, Z. Zhang<sup>24<\/sup>, J. Lu<sup>25<\/sup>, W. Yang<sup>26<\/sup>, G. Li<sup>27<\/sup>, J. Feng<sup>28<\/sup>, D. Lv<sup>29<\/sup>, L. Wu<sup>30<\/sup>, Y. Fang<sup>31<\/sup>, Y. Wang<sup>32<\/sup>, Y. Zhao<sup>33<\/sup>, B. Cao<sup>34<\/sup>, W. Zhu<sup>35<\/sup>, Z. Zhuang<sup>36<\/sup>, Q. Li<sup>37<\/sup>, M. Wang<sup>38<\/sup>, H. Zhou<sup>38<\/sup>, X. Dong<sup>39<\/sup>, S. Hu<sup>40<\/sup>, J. Fang<sup>41<\/sup>, Y. Zhang<sup>42<\/sup>, W. Wang<sup>42<\/sup>, Z. Xiang<sup>42<\/sup>, Z. Shi<sup>42<\/sup>, L. Zhang<sup>42<\/sup>, S. Lu<sup>1<\/sup>; <br\/><sup>1<\/sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, <sup>2<\/sup>The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, <sup>3<\/sup>Tianjin Medical University Cancer Institute & Hospital, Tianjin, China, <sup>4<\/sup>Cancer Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China, <sup>5<\/sup>The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, <sup>6<\/sup>Linyi Cancer Hospital, Linyi, China, <sup>7<\/sup>The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China, <sup>8<\/sup>Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, <sup>9<\/sup>The Affiliated Bethune Hospital of Shanxi Medical University, Taiyuan, China, <sup>10<\/sup>Fujian Provincial Cancer Hospital, Fuzhou, China, <sup>11<\/sup>The Third Xiangya Hospital of Central South University, Changsha, China, <sup>12<\/sup>Shandong Cancer Hospital, Jinan, China, <sup>13<\/sup>The First Hospital of China Medical University, Shenyang, China, <sup>14<\/sup>The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, <sup>15<\/sup>Yantai Yuhuangding Hospital, Yantai, China, <sup>16<\/sup>The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, <sup>17<\/sup>Jiangxi Cancer Hospital, Nanchang, China, <sup>18<\/sup>Tangshan Cancer Hospital, Tangshan, China, <sup>19<\/sup>Henan Provincial People's Hospital, Zhengzhou, China, <sup>20<\/sup>Xuzhou Central Hospital, Xuzhou, China, <sup>21<\/sup>The Affiliated Hospital of Qingdao University, Qingdao, China, <sup>22<\/sup>The First Hospital of Jilin University, Changchun, China, <sup>23<\/sup>Harbin Medical University Cancer Hospital, Harbin, China, <sup>24<\/sup>Anhui Provincial Cancer Hospital, Hefei, China, <sup>25<\/sup>Nantong Tumor Hospital, Nantong, China, <sup>26<\/sup>Shanxi Cancer Hospital, Taiyuan, China, <sup>27<\/sup>Yunnan Cancer Hospital, Kunming, China, <sup>28<\/sup>Jiangsu Cancer Hospital, Nanjing, China, <sup>29<\/sup>Taizhou Hospital of Zhejiang Province, Taizhou, China, <sup>30<\/sup>Hunan Cancer Hospital, Changsha, China, <sup>31<\/sup>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, <sup>32<\/sup>General Hospital of Ningxia Medical University, Yinchuan, China, <sup>33<\/sup>The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, <sup>34<\/sup>Peking University Third Hospital, Beijing, China, <sup>35<\/sup>Baotou Central Hospital, Baotou, China, <sup>36<\/sup>The Second Affiliated Hospital of Soochow University, Suzhou, China, <sup>37<\/sup>Affiliated Hospital of Chengde Medical University, Chengde, China, <sup>38<\/sup>The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, <sup>39<\/sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, <sup>40<\/sup>Hubei Cancer Hospital, Wuhan, China, <sup>41<\/sup>Beijing Cancer Hospital, Beijing, China, <sup>42<\/sup>InventisBio Co., Ltd, Shanghai, China","CSlideId":"","ControlKey":"bf7f0695-42de-43ab-a5af-66bcce4268df","ControlNumber":"9755","DisclosureBlock":"<b>&nbsp;Z. Li, <\/b> <br><b>Astra Zeneca<\/b> Other, Speaker fees. <br><b>Roche<\/b> Other, Speaker fees. <br><b>Hansoh<\/b> Other, Speaker fees.<br><b>X. Dang, <\/b> None..<br><b>D. Huang, <\/b> None..<br><b>S. Jin, <\/b> None..<br><b>W. Li, <\/b> None..<br><b>J. Shi, <\/b> None..<br><b>X. Wang, <\/b> None..<br><b>Y. Zhang, <\/b> None..<br><b>Z. Song, <\/b> None..<br><b>J. Zhang, <\/b> None..<br><b>W. Zhuang, <\/b> None..<br><b>X. Liu, <\/b> None.&nbsp;<br><b>L. Jiang, <\/b> <br><b>InventisBio<\/b> Grant\/Contract, Other, Speaker fees; Consultant\/advisory board.<br><b>X. Meng, <\/b> None..<br><b>M. Zhao, <\/b> None.&nbsp;<br><b>J. Zhou, <\/b> <br><b>InventisBio<\/b> Grant\/Contract, Other, Speaker fees; Consultant\/advisory board.<br><b>L. Zhang, <\/b> None.&nbsp;<br><b>P. Wang, <\/b> <br><b>InventisBio<\/b> Grant\/Contract, Speaker fees; Consultant\/advisory board.<br><b>H. Luo, <\/b> None..<br><b>J. Yang, <\/b> None..<br><b>S. Cang, <\/b> None..<br><b>X. Wang, <\/b> None..<br><b>J. Wang, <\/b> None..<br><b>J. Cui, <\/b> None..<br><b>Y. Yu, <\/b> None..<br><b>Z. Zhang, <\/b> None.&nbsp;<br><b>J. Lu, <\/b> <br><b>InventisBio<\/b> Grant\/Contract, Other, Speaker fees; Consultant\/advisory board.<br><b>W. Yang, <\/b> None..<br><b>G. Li, <\/b> None..<br><b>J. Feng, <\/b> None..<br><b>D. Lv, <\/b> None.&nbsp;<br><b>L. Wu, <\/b> <br><b>InventisBio<\/b> Grant\/Contract, Other, Speaker fees; Consultant\/advisory board.<br><b>Y. Fang, <\/b> None.&nbsp;<br><b>Y. Wang, <\/b> <br><b>InventisBio<\/b> Grant\/Contract, Other, Speaker fees; Consultant\/advisory board.<br><b>Y. Zhao, <\/b> None..<br><b>B. Cao, <\/b> None.&nbsp;<br><b>W. Zhu, <\/b> <br><b>InventisBio<\/b> Grant\/Contract, Other, Speaker fees; Consultant\/advisory board.<br><b>Z. Zhuang, <\/b> None..<br><b>Q. Li, <\/b> None..<br><b>M. Wang, <\/b> None..<br><b>H. Zhou, <\/b> None..<br><b>X. Dong, <\/b> None..<br><b>S. Hu, <\/b> None..<br><b>J. Fang, <\/b> None.&nbsp;<br><b>Y. Zhang, <\/b> <br><b>InventisBio<\/b> Employment. <br><b>W. Wang, <\/b> <br><b>InventisBio<\/b> Employment. <br><b>Z. Xiang, <\/b> <br><b>InventisBio<\/b> Employment, Stock. <br><b>Z. Shi, <\/b> <br><b>InventisBio<\/b> Employment, Stock. <br><b>L. Zhang, <\/b> <br><b>InventisBio<\/b> Employment, Stock. <br><b>S. Lu, <\/b> <br><b>Astra Zeneca<\/b> Grant\/Contract, Other, Consulting fees; Speaker fees. <br><b>Hutchison<\/b> Grant\/Contract, Other, Consulting fees. <br><b>BMS<\/b> Grant\/Contract. <br><b>Heng Rui<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract, Other, Consulting fees; Speaker fees. <br><b>BoehringerIngelheim<\/b> Other, Consulting fees. <br><b>Hutchison MediPharma<\/b> Other, Consulting fees. <br><b>Simcere<\/b> Other, Consulting fees. <br><b>ZaiLab<\/b> Other, Consulting fees. <br><b>GenomiCare<\/b> Other, Consulting fees. <br><b>Hansoh<\/b> Other, Speaker fees.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11567","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT246","PresenterBiography":null,"PresenterDisplayName":"Ziming Li, PhD","PresenterKey":"2379b049-7f74-46d7-af62-d3d102db3f74","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT246. Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),NSCLC,SKB264,Trop-2,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"W. Fang<sup>1<\/sup>, Y. Cheng<sup>2<\/sup>, Z. Chen<sup>3<\/sup>, W. Wang<sup>4<\/sup>, Y. Li<sup>5<\/sup>, Y. Yin<sup>6<\/sup>, X. Li<sup>7<\/sup>, H. Xu<sup>8<\/sup>, G. Yu<sup>9<\/sup>, Y. Mi<sup>10<\/sup>, Z. A. Wainberg<sup>11<\/sup>, J. Rodon<sup>12<\/sup>, X. Wang<sup>13<\/sup>, X. Wang<sup>14<\/sup>, X. Zhang<sup>15<\/sup>, <b>X. Jin<\/b><sup>15<\/sup>, L. Lu<sup>15<\/sup>, J. Ge<sup>15<\/sup>, J. Li<sup>16<\/sup>, L. Zhang<sup>1<\/sup>; <br\/><sup>1<\/sup>Sun Yat-sen University Cancer Center, Guangzhou, China, <sup>2<\/sup>Jilin Cancer Hospital, Changchun, China, <sup>3<\/sup>The Second Affiliated Hospital of Anhui Medical University, Hefei, China, <sup>4<\/sup>Hunan Cancer Hospital, Changsha, China, <sup>5<\/sup>Chongqing University Cancer Hospital, Chongqing, China, <sup>6<\/sup>Jiangsu Province Hospital, Nanjing, China, <sup>7<\/sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, <sup>8<\/sup>Hubei Cancer Hospital, Wuhan, China, <sup>9<\/sup>Weifang People's Hospital, Weifang, China, <sup>10<\/sup>The First Affiliated Hospital of Xiamen University, Xiamen, China, <sup>11<\/sup>University of California Los Angeles, Los Angeles, CA, <sup>12<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX, <sup>13<\/sup>Xuzhou Central Hospital, Xuzhou, China, <sup>14<\/sup>Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China, <sup>15<\/sup>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China, <sup>16<\/sup>Shanghai East Hospital, Shanghai, China","CSlideId":"","ControlKey":"b3de01cc-2f1f-42bb-bd72-24c283dc508d","ControlNumber":"10274","DisclosureBlock":"&nbsp;<b>W. Fang, <\/b> None..<br><b>Y. Cheng, <\/b> None..<br><b>Z. Chen, <\/b> None..<br><b>W. Wang, <\/b> None..<br><b>Y. Li, <\/b> None..<br><b>Y. Yin, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>H. Xu, <\/b> None..<br><b>G. Yu, <\/b> None..<br><b>Y. Mi, <\/b> None.&nbsp;<br><b>Z. A. Wainberg, <\/b> <br><b>AstraZeneca<\/b> Other, Consultant. <br><b>Bristol-Myers Squibb<\/b> Other, Consultant. <br><b>Novartis<\/b> Other, Consultant. <br><b>AngioDynamics, Inc.<\/b> Other, Consultant. <br><b>Eli LIly<\/b> Other, Consultant. <br><b>Astellas Pharma<\/b> Other, Consultant. <br><b>Daichi Sankyo Company<\/b> Other, Consultant. <br><b>Ipsen Biopharmaceuticals, Inc.<\/b> Other, Consultant. <br><b>Amgen<\/b> Other, Consultant. <br><b>Merck<\/b> Other, Consultant. <br><b>J. Rodon, <\/b> <br><b>European Society for Medical Oncology; Loxo Oncology<\/b> Travel. <br><b>Ellipses Pharma; Molecular Partners; IONCTURA; Sardona; Mekanistic; Amgen; Merus; MonteRosa; Aadi; Bridgebio<\/b> Other, Receiving consulting and travel fees. <br><b>Vall d'Hebron Institute of Oncology\/Ministero De Empleo Y Seguridad Social; Chinese University of Hong Kong; Boxer Capital; LLC; Tang Advisors; LLC; Guidepoint<\/b> Other, Consulting fees. <br><b>Blueprint Medicines; Merck Sharp & Dohme; Hummingbird; AstraZenneca; Yingli; Vall d'Hebron Institute of Oncology\/Cancer Core Europe<\/b> Other, Research funding. <br><b>Cancer Core Europe; Symphogen; BioAlta; Pfizer; Kelun-Biotech; GlaxoSmithKline; Taiho; Roche Pharmaceuticals; Hummingbird; Yingli; Bicycle Therapeutics; Merus; AadiBioscience; ForeBio; Loxo Oncology;<\/b> Other, Serving as investigator in clinical trials.<br><b>X. Wang, <\/b> None..<br><b>X. Wang, <\/b> None.&nbsp;<br><b>X. Zhang, <\/b> <br><b>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/b> Employment. <br><b>X. Jin, <\/b> <br><b>Sichuan Kelun-Biotech Biopharmaceutical<\/b> Stock. <br><b>L. Lu, <\/b> <br><b>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/b> Employment. <br><b>J. Ge, <\/b> <br><b>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/b> Employment.<br><b>J. Li, <\/b> None..<br><b>L. Zhang, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11568","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT247","PresenterBiography":null,"PresenterDisplayName":"Xiaoping Jin, Unknown","PresenterKey":"00da82da-e152-413b-b25d-81b9085d2f3b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT247. Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"NSCLC,HER2 mutant,Antibody-drug conjugate (ADC),Trastuzumab deruxtecan,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Cheng<\/b><sup>1<\/sup>, L. Wu<sup>2<\/sup>, Y. Fang<sup>3<\/sup>, Y. Fan<sup>4<\/sup>, X. Li<sup>5<\/sup>, M. Zhang<sup>6<\/sup>, Y. Yu<sup>7<\/sup>, Y. Yao<sup>8<\/sup>, R. Xu<sup>9<\/sup>, J. Guo<sup>10<\/sup>, H. Yang<sup>11<\/sup>, J. Fang<sup>12<\/sup>, F. Luo<sup>13<\/sup>, X. Min<sup>14<\/sup>, K.-j. Tang<sup>15<\/sup>, J. Hu<sup>16<\/sup>, Y. Chen<sup>17<\/sup>, R. Mao<sup>17<\/sup>, V. Zhang<sup>17<\/sup>, D. Li<sup>18<\/sup>; <br\/><sup>1<\/sup>Medical Oncology, Jilin Cancer Hospital, Changchun, China, <sup>2<\/sup>2nd Department of Thoracic Medicine, Hunan Cancer Hospital, Changsha, China, <sup>3<\/sup>Medical Oncology, Sir Run Run Shaw Hospital School of Medicine, Zhejiang University, Hangzhou, China, <sup>4<\/sup>Department of Medical Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou, China, <sup>5<\/sup>Oncology Department 2nd Ward, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, <sup>6<\/sup>Oncology Department, The Second Hospital of Anhui Medical University, Hefei, China, <sup>7<\/sup>3rd Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China, <sup>8<\/sup>Medical Oncology, The First Affiliated hospital of Xi’an Jiaotong University, Xi’an, China, <sup>9<\/sup>Medical Oncology, Shenzhen People's Hospital, Shenzhen, China, <sup>10<\/sup>1st Respiratory Medicine, Shandong Cancer Hospital, Jinan, China, <sup>11<\/sup>Pulmonary and Critical Care Medicine, Xiangya Hospital Central South University, Changsha, China, <sup>12<\/sup>2nd Department of Thoracic Medicine, Beijing Cancer Hospital, Beijing, China, <sup>13<\/sup>Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, <sup>14<\/sup>Neoplasm Radiotherapy Department, Anhui Chest Hospital, Hefei, China, <sup>15<\/sup>Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, <sup>16<\/sup>Department of Pulmonary and Critical Care Medicine, Shanghai Geriatric Center, Zhongshan Hospital, Fudan University, Shanghai, China, <sup>17<\/sup>AstraZeneca, Shanghai, China, <sup>18<\/sup>Department of Medical Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China","CSlideId":"","ControlKey":"6b4098c1-9ad1-4450-8ef0-070341c9a6b1","ControlNumber":"9624","DisclosureBlock":"&nbsp;<b>Y. Cheng, <\/b> None..<br><b>L. Wu, <\/b> None..<br><b>Y. Fang, <\/b> None..<br><b>Y. Fan, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>M. Zhang, <\/b> None..<br><b>Y. Yu, <\/b> None..<br><b>Y. Yao, <\/b> None..<br><b>R. Xu, <\/b> None..<br><b>J. Guo, <\/b> None..<br><b>H. Yang, <\/b> None..<br><b>J. Fang, <\/b> None..<br><b>F. Luo, <\/b> None..<br><b>X. Min, <\/b> None..<br><b>K. Tang, <\/b> None..<br><b>J. Hu, <\/b> None.&nbsp;<br><b>Y. Chen, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>R. Mao, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>V. Zhang, <\/b> <br><b>AstraZeneca<\/b> Employment.<br><b>D. Li, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11569","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT248","PresenterBiography":null,"PresenterDisplayName":"Xiuzhi Wu","PresenterKey":"6b0d90dd-f5cd-4b74-8b9d-90278457ab77","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT248. Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase&#8239;2 DESTINY-Lung05 (DL-05) trial","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase&#8239;2 DESTINY-Lung05 (DL-05) trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pembrolizumab,Chemotherapy,Immunotherapy,Anti-PD-1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"C. Aggarwal<sup>1<\/sup>, J. Stevenson<sup>2<\/sup>, D. M. Kowalski<sup>3<\/sup>, T. Cs&#337;szi<sup>4<\/sup>, N. Peled<sup>5<\/sup>, B. Cho<sup>6<\/sup>, B. Rubio-Viqueira<sup>7<\/sup>, J. Niu<sup>8<\/sup>, D. P. Carbone<sup>9<\/sup>, S. M. Arnold<sup>10<\/sup>, M. M. Awad<sup>11<\/sup>, J. F. Gainor<sup>12<\/sup>, S. Rao<sup>13<\/sup>, A. S. Tsao<sup>14<\/sup>, H. Zhou<sup>15<\/sup>, O. O. Akala<sup>15<\/sup>, E. Chartash<sup>15<\/sup>, <b>E. Nadal<\/b><sup>16<\/sup>; <br\/><sup>1<\/sup>Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, <sup>2<\/sup>Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, <sup>3<\/sup>Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, <sup>4<\/sup>Hetenyi G Korhaz Onkologiai Kozpont, Szolnok, Hungary, <sup>5<\/sup>Shaare Zedek Medical Center, Jerusalem, Israel, <sup>6<\/sup>Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>7<\/sup>Hospital Universitario Quironsalud Madrid, Madrid, Spain, <sup>8<\/sup>Banner MD Anderson Cancer Center, Gilbert, AZ, <sup>9<\/sup>The Ohio State University Comprehensive Cancer Center, Columbus, OH, <sup>10<\/sup>University of Kentucky Markey Cancer Center, Lexington, KY, <sup>11<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>12<\/sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, <sup>13<\/sup>Ascension Saint Agnes Health Center Catonsville, Catonsville, MD, <sup>14<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX, <sup>15<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>16<\/sup>Institu Català d’Oncologia, L’Hospitalet, Barcelona, Spain","CSlideId":"","ControlKey":"79e17161-1dcf-4f73-a828-60d87ecb571d","ControlNumber":"10626","DisclosureBlock":"<b>&nbsp;C. Aggarwal, <\/b> <br><b>AstraZeneca, Genentech, Incyte, Macrogenics, Medimmune, Lilly@Loxo and Merck Sharp & Dohme<\/b> Other, Institutional research funding. <br><b>Genentech, Lilly, Celgene, Merck Sharp & Dohme, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo\/ AstraZeneca, Regeneron\/ Sanofi, Eisai, BeiGene, Turning Point<\/b> Other, consultation fees. <br><b>Pfizer, Janssen, Boehringer Ingelheim<\/b> Other, consultation fees. <br><b>J. Stevenson, <\/b> <br><b>Arcus Biosciences<\/b> Other, Scientific advisory board. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Black Diamond Therapeutics; Alpha Oncology; Amgen<\/b> Other, Research funding to Institution. <br><b>D. M. Kowalski, <\/b> <br><b>MSD, Pfizer, Amgen, BMS, AstraZeneca, Sanofi-Aventis, Boehringer-Ingelheim, Takeda, Roche, Novartis, Johnson & Johnson, Merck KGaA.<\/b> Other, Advisory Board and consultancy. <br><b>T. Cs&#337;szi, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Study funding to the institution. <br><b>N. Peled, <\/b> <br><b>AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Novartis, Pfizer, Roche, Takeda<\/b> Other, Honoraria. <br><b>AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, MSD, Novartis, Pfizer, Roche<\/b> Other, Consulting or advisory role. <br><b>MSD Oncology, Roche\/Genentech, AstraZeneca, Takeda, Merck Serono, Novartis<\/b> Other, Research funding. <br><b>Roche\/Genentech, MSD Oncology, AstraZeneca, Pfizer<\/b> Other, Travel, accommodations, expenses. <br><b>B. Cho, <\/b> <br><b>Champions Oncology, Crown Bioscience, Imagen, PearlRiver Bio GmbH<\/b> Other, Royalties (PDX, PDO, PDC Licensing Contract – not patent). <br><b>MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, Abbvie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Oncology<\/b> Other, Grant\/Research support\/Funding statement. <br><b>CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST, Bridgebio therapeutics, Yuhan<\/b> Other, Grant\/Research support\/Funding statement. <br><b>ImmuneOncia, Illumina, Kanaph therapeutics, Therapex, JINTSbio, Hanmi, CHA Bundang Medical Center, Vertical Bio AG<\/b> Other, Grant\/Research support\/Funding statement. <br><b>Abion, BeiGene, Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N<\/b> Other, Consultancy. <br><b>Imnewrun Biosciences Inc., Janssen, Takeda, MSD, Janssen, Medpacto, Blueprint medicines, RandBio, Hanmi<\/b> Other, Consultancy. <br><b>KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc, J INTS Bio, Therapex Co., Ltd, Gilead, Amgen<\/b> Other, Advisory board. <br><b>ASCO, AstraZeneca, Guardant, Roche, ESMO, IASLC, Korean Cancer Association, Korean Society of Medical Oncology, Korean Society of Thyroid-Head and Neck Surgery, Korean Cancer Study Group<\/b> Other, Invited speaker. <br><b>Novartis, MSD, The Chinese Thoracic Oncology Society, Pfizer.<\/b> Other, Invited speaker. <br><b>TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO<\/b> Stock, Other, Stocks\/shares. <br><b>DAAN Biotherapeutics<\/b> Other, Founder. <br><b>J INTS BIO<\/b> Other, Member of the board of directors. <br><b>B. Rubio-Viqueira, <\/b> <br><b>Bristol Myers Squibb, Janssen, Lilly, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and GSK<\/b> Other, Invited speaker. <br><b>Lilly, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Advisory board. <br><b>Roche\/Genentech, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Janssen and GSK<\/b> Other, Travel, accommodations, expenses. <br><b>J. Niu, <\/b> <br><b>AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Mirati Therapeutics, Takeda, Sanofi, Pfizer, G1 Therapeutics<\/b> Other, Consulting and Advisory role. <br><b>D. P. Carbone, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Study funding to the institution. <br><b>S. M. Arnold, <\/b> <br><b>AstraZeneca Pharmaceuticals, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Exelixis, Inc., Kura Oncology, Syneos Health, Abbvie Inc., Kinnate Biopharma Incorp<\/b> Other, Study funding to the institution. <br><b>Ellipses Pharma Limited, Gilead Sciences Inc., Incyte Corp., Eli Lilly and Company, BeiGene USA Incorp., Bicara Therapeutics, Inc., Lisata Therapeutics Inc., Lab Corp, Inc., Fortrea Inc.<\/b> Other, Study funding to the institution. <br><b>M. M. Awad, <\/b> <br><b>Merck, Pfizer, Bristol-Myers Squibb, Foundation Medicine, Novartis, Gritstone Oncology, Mirati Therapeutics, EMD Serono, AstraZeneca, Instil Bio, Regeneron, Janssen, Affini-T Therapeutics<\/b> Other, Consulting or advisory role. <br><b>Genentech\/Roche, Lilly, AstraZeneca, Bristol-Myers Squibb, Amgen<\/b> Other, Research funding. <br><b>Bristol Myers Squibb Foundation<\/b> Other, Travel accomodations and expenses. <br><b>J. F. Gainor, <\/b> <br><b>Amgen, AstraZeneca, Mariana Therapeutics, Mirati Therapeutics, Merus Pharmaceuticals, Nuvalent, Pfizer, Novocure, AI Proteins, Novartis, Silverback Therapeutics, Sanofi, Blueprint Medicines<\/b> Other, Served as a compensated consultant. <br><b>Bristol Myers Squibb, Genentech, Gilead Sciences, ITeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Lilly\/Loxo, MSD, Moderna Therapeutics, Takeda<\/b> Other, Served as a compensated consultant. <br><b>Novartis, MSD, Novartis, Pfizer, Takeda<\/b> Other, Honorarium. <br><b>Adaptimmune, Alexo Therapeutics, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Jounce Therapeutics, MSD, Moderna Therapeutics<\/b> Other, Institutional research funding. <br><b>Novartis, NextPoint Therapeutics, Palleon Pharmaceuticals<\/b> Other, Institutional research funding. <br><b>Novartis, Genentech and Takeda<\/b> Other, Research support. <br><b>AI Proteins<\/b> Other, Equity. <br><b>Ironwood Pharmaceuticals<\/b> Other, Has an immediate family member who has equity in and is employed by. <br><b>S. Rao, <\/b> <br><b>AstraZeneca<\/b> Other, Speaker Bureau. <br><b>A. S. Tsao, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Study funding to the institution. <br><b>H. Zhou, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>O. O. Akala, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>E. Chartash, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>E. Nadal, <\/b> <br><b>Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi, Illumina, Janssen, Lilly, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Pfizer; Qiagen; Roche; Sanofi; Takeda<\/b> Other, Invited speaker (financial, personal). <br><b>Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Lilly, Merck Serono, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Advisory board (financial, personal). <br><b>Pfizer; Pierre Fabre; Qiagen; Regeneron; Roche; Takeda; Sanofi<\/b> Other, Advisory board (financial, personal). <br><b>Bristol Myers Squibb, Merck Serono, Roche<\/b> Other, Funding support (Personal and Institutional; no financial interest). <br><b>Apollomics, Pfizer, Roche<\/b> Other, Advisory role (non-financial). <br><b>Spanish Lung Cancer Group (GECP)<\/b> Other, Member of the Steering Committee.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11570","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT249","PresenterBiography":null,"PresenterDisplayName":"Sarah Nissen","PresenterKey":"b9c6d2bd-f0bd-465d-8d52-b78e5681fe8d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT249. Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),Lung cancer: non-small cell,Targeted therapy,MET inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J.-H. Yang<\/b><sup>1<\/sup>, Y.-M. Chen<sup>2<\/sup>, U. Batra<sup>3<\/sup>, K. Do<sup>4<\/sup>, P. Sitthideatphaiboon<sup>5<\/sup>, P. Danchaivijitr<sup>6<\/sup>, K.-Y. Lee<sup>7<\/sup>, J. Chindaprasirt<sup>8<\/sup>, C.-T. Yang<sup>9<\/sup>, G.-C. Chang<sup>10<\/sup>, C. Charoentum<sup>11<\/sup>, T. Ungtrakul<sup>12<\/sup>, J. Moran<sup>13<\/sup>, R. Hartmaier<sup>14<\/sup>, M. Haskins<sup>15<\/sup>, W. Xu<sup>16<\/sup>, J. W. Riess<sup>17<\/sup>; <br\/><sup>1<\/sup>Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Centre, Taipei, Taiwan, <sup>2<\/sup>Department of Chest Medicine, Taipei Veterans General Hospital, and School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan, <sup>3<\/sup>Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research, Delhi, India, <sup>4<\/sup>Department of Medical Oncology, Vietnam National Cancer Hospital-K Hospital, Hanoi, Viet Nam, <sup>5<\/sup>Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand, <sup>6<\/sup>Division of Medical Oncology, Siriraj Hospital, Bangkok, Thailand, <sup>7<\/sup>Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan, <sup>8<\/sup>Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, <sup>9<\/sup>Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, <sup>10<\/sup>Department of Internal Medicine, Chung Shan Med Univ Hospital, Taichung City, Taiwan, <sup>11<\/sup>Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, <sup>12<\/sup>Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand, <sup>13<\/sup>Department of Clinical Oncology, Centro de Urologia, Buenos Aires, Argentina, <sup>14<\/sup>Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, <sup>15<\/sup>Oncology Biometrics, Oncology R&D, AstraZeneca, Gaithersburg, MA, <sup>16<\/sup>Oncology Late Development, Oncology R&D, AstraZeneca, New York, NY, <sup>17<\/sup>University of California, UC Davis Comprehensive Cancer Center, Sacramento, CA","CSlideId":"","ControlKey":"2a054232-0321-4754-8484-ce483fcbeb86","ControlNumber":"9920","DisclosureBlock":"<b>&nbsp;J. Yang, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Advisory Board, Coordinating PI, Steering Committee member. <br><b>Amgen<\/b> Other, Advisory Board. <br><b>Bayer<\/b> Other, Advisory Board. <br><b>Boehringer Ingelheim<\/b> Other, Advisory Board. <br><b>Bristol Myers Squibb<\/b> Other, Advisory Board. <br><b>Daiichi Sankyo<\/b> Other, Advisory Board, Steering Committee member. <br><b>Eli Lilly<\/b> Other, Advisory Board, Steering Committee member. <br><b>Merck KGaA<\/b> Other, Advisory Board. <br><b>Merck Sharp & Dohme<\/b> Other, Advisory Board, Coordinating PI, Steering Committee member. <br><b>Novartis<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Other, Advisory Board. <br><b>Roche\/Genentech<\/b> Other, Advisory Board. <br><b>Takeda<\/b> Other, Advisory Board, Steering Committee member. <br><b>Yuhan Pharmaceuticals<\/b> Other, Advisory Board, Steering Committee member. <br><b>Janssen<\/b> Other, Advisory Board, Steering Committee member. <br><b>Puma Technology<\/b> Other, Advisory Board. <br><b>Gilead<\/b> Other, Advisory Board. <br><b>GSK<\/b> Other, Advisory Board. <br><b>Dizal Pharmaceutical<\/b> Other, Advisory Board, Coordinating PI. <br><b>Memberships<\/b> Other, ASCO; ESMO; IASLC. <br><b>Y. Chen, <\/b> <br><b>Roche<\/b> Other, Advisory Council and Consulting fee. <br><b>AstraZeneca<\/b> Other, Advisory Council and Consulting fee. <br><b>Eli Lily<\/b> Other, Advisory Council and Consulting fee. <br><b>Boehringer Ingelheim<\/b> Other, Advisory Council and Consulting fee. <br><b>Merck Sharp & Dohme<\/b> Other, Advisory Council and Consulting fee. <br><b>Chugai Pharmaceutical Co., Ltd.<\/b> Other, Advisory Council and Consulting fee. <br><b>Ono Pharmaceutical Co., Ltd.<\/b> Other, Advisory Council and Consulting fee. <br><b>Bristol Myers Squibb<\/b> Other, Advisory Council and Consulting fee.<br><b>U. Batra, <\/b> None..<br><b>K. Do, <\/b> None..<br><b>P. Sitthideatphaiboon, <\/b> None..<br><b>P. Danchaivijitr, <\/b> None..<br><b>K. Lee, <\/b> None..<br><b>J. Chindaprasirt, <\/b> None..<br><b>C. Yang, <\/b> None.&nbsp;<br><b>G. Chang, <\/b> <br><b>F. Hoffman-La Roche Ltd.<\/b> Other, Honoraria. <br><b>Eli Lilly and Company<\/b> Other, Honoraria. <br><b>AstraZeneca<\/b> Other, Honoraria. <br><b>Pfizer<\/b> Other, Honoraria. <br><b>Boehringer Ingelheim<\/b> Other, Honoraria. <br><b>Bristol Myers Squibb<\/b> Other, Honoraria. <br><b>Merck Sharp & Dohme<\/b> Other, Honoraria. <br><b>C. Charoentum, <\/b> <br><b>Chiang Mai University<\/b> Employment. <br><b>AstraZeneca<\/b> Other, Research funding. <br><b>Roche<\/b> Other, Research funding. <br><b>Merck Sharp & Dohme<\/b> Other, Research funding.<br><b>T. Ungtrakul, <\/b> None..<br><b>J. Moran, <\/b> None.&nbsp;<br><b>R. Hartmaier, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>Inventor<\/b> Patent, Inventor on patent US11066709B2 (no fees or royalties). <br><b>M. Haskins, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>W. Xu, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>J. W. Riess, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Travel, Grant to institution. <br><b>IO Biotech<\/b> Grant\/Contract, Travel, Grant to institution. <br><b>Novartis<\/b> Grant\/Contract, To institution. <br><b>ArriVent<\/b> Grant\/Contract, To institution. <br><b>Kinnate<\/b> Grant\/Contract, To institution. <br><b>Revolution Medicines<\/b> Grant\/Contract, To institution. <br><b>Nuvalent<\/b> Grant\/Contract, To institution. <br><b>Summit<\/b> Grant\/Contract, To institution. <br><b>Honoraria<\/b> Other, Genentech; Daiichi Sankyo; Catalyst; SeaGen; Amgen; Regeneron; Sanofi; Bayer; Merus NV; BeiGene; Jazz; Bristol Myers Squibb.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11572","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT251","PresenterBiography":null,"PresenterDisplayName":"James Chih-Hsin Yang, MD;PhD","PresenterKey":"0c20c214-78cf-457e-bcd2-9fa5aa317341","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT251. Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"NSCLC,EGFR,Survival,Nicotinamide,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"C.-K. Park<sup>1<\/sup>, H.-J. Oh<sup>1<\/sup>, S.-C. Bae<sup>2<\/sup>, I.-J. Oh<sup>1<\/sup>, K.-M. Jung<sup>2<\/sup>, D.-M. Kim<sup>2<\/sup>, J.-W. Lee<sup>2<\/sup>, C. Kang<sup>2<\/sup>, I. Park<sup>2<\/sup>, <b>Y.-C. Kim<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Chonnam National Univ. Hwasun Hospital, Jeonnam County, Korea, Republic of, <sup>2<\/sup>Chungbuk National University, Cheongju, Korea, Republic of","CSlideId":"","ControlKey":"15fa88ab-fca7-46bc-8a49-3bbe92902ba0","ControlNumber":"9840","DisclosureBlock":"&nbsp;<b>C. Park, <\/b> None..<br><b>H. Oh, <\/b> None..<br><b>S. Bae, <\/b> None.&nbsp;<br><b>I. Oh, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract.<br><b>K. Jung, <\/b> None..<br><b>D. Kim, <\/b> None..<br><b>J. Lee, <\/b> None..<br><b>C. Kang, <\/b> None.&nbsp;<br><b>I. Park, <\/b> <br><b>Engineering Foundation and funding from the Cooperative Research Program for Agriculture Science & Technology Development of Korea (PJ009588)<\/b> Grant\/Contract. <br><b>Y. Kim, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11573","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT252","PresenterBiography":"","PresenterDisplayName":"Young-Chul Kim, MD","PresenterKey":"c5a423a5-cf77-406d-9596-fa80ccdd17be","PresenterPhoto":"https:\/\/files.abstractsonline.com\/assocphotos\/101\/c5a423a5-cf77-406d-9596-fa80ccdd17be.profile.jpg","SearchResultActions":null,"SearchResultBody":"CT252. Nicotinamide in combination with EGFR-TKIs for the treatment of stage IV lung adenocarcinoma with EGFR mutations: A randomized double-blind (Phase IIb) trial","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Nicotinamide in combination with EGFR-TKIs for the treatment of stage IV lung adenocarcinoma with EGFR mutations: A randomized double-blind (Phase IIb) trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pembrolizumab,Chemotherapy,Immuno-oncology,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Rodríguez-Abreu<\/b><sup>1<\/sup>, M. Hochmair<sup>2<\/sup>, B. Cho<sup>3<\/sup>, T. Cs&#337;szi<sup>4<\/sup>, T. Shentzer Kutiel<sup>5<\/sup>, V. Müller<sup>6<\/sup>, M.-J. Ahn<sup>7<\/sup>, D. Kowalski<sup>8<\/sup>, M. Maio<sup>9<\/sup>, V. Moiseyenko<sup>10<\/sup>, A. Navarro<sup>11<\/sup>, J. Niu<sup>12<\/sup>, A. S. Fung<sup>13<\/sup>, C. Lips<sup>14<\/sup>, H. Zhou<sup>15<\/sup>, B. Zhao<sup>15<\/sup>, H. Lara-Guerra<sup>15<\/sup>, N. Peled<sup>16<\/sup>; <br\/><sup>1<\/sup>Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain, <sup>2<\/sup>Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria, <sup>3<\/sup>Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>4<\/sup>Hetenzyi Geza Korhaz, Szolnok, Hungary, <sup>5<\/sup>Rambam Health Care Campus, Haifa, Israel, <sup>6<\/sup>Department of Pulmonology, Semmelweis University, Budapest, Hungary, <sup>7<\/sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, <sup>8<\/sup>Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, <sup>9<\/sup>University of Siena and Center for Immuno-Oncology, Department of Oncology, University Hospital of Siena, Siena, Italy, <sup>10<\/sup>Clinical and Research Center of Specialized Types of Medical Care (Oncological), Saint-Petersburg, Russian Federation, <sup>11<\/sup>Vall d'Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, <sup>12<\/sup>Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, <sup>13<\/sup>Kingston Health Sciences Centre, Kingston, ON, Canada, <sup>14<\/sup>Kantonsspital St. Gallen, Department of Medical Oncology, St. Gallen, Switzerland, <sup>15<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>16<\/sup>Shaare Zedek Medical Center, Jerusalem, Israel","CSlideId":"","ControlKey":"c1d85036-9826-4bf1-9377-13491d00d905","ControlNumber":"10466","DisclosureBlock":"<b>&nbsp;D. Rodríguez-Abreu, <\/b> <br><b>Roche, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Eli Lilly, Pfizer, Regeneron and Novartis<\/b> Other, Personal fees\/honoraria for consultancy and lectures. <br><b>Roche, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; and Novartis<\/b> Other, Travel expenses. <br><b>Bristol Myers Squibb<\/b> Other, Grant support for institutional studies. <br><b>M. Hochmair, <\/b> <br><b>MSD, Roche, Lilly, AstraZeneca, Takeda.<\/b> Other, Lectures and advisory boards. <br><b>B. Cho, <\/b> <br><b>Champions Oncology, Crown Bioscience, Imagen, PearlRiver Bio GmbH<\/b> Other, Royalties (PDX, PDO, PDC Licensing Contract – not patent). <br><b>MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, Abbvie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Oncology<\/b> Other, Grant\/Research support\/Funding statement. <br><b>CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST, Bridgebio therapeutics, Yuhan, ImmuneOncia, Illumina<\/b> Other, Grant\/Research support\/Funding statement. <br><b>Kanaph therapeutics, Therapex, JINTSbio, Hanmi, CHA Bundang Medical Center, Vertical Bio AG.<\/b> Other, Grant\/Research support\/Funding statement. <br><b>Abion, BeiGene, Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell<\/b> Other, Consultancy. <br><b>Guardant, HK Inno-N, Imnewrun Biosciences Inc., Janssen, Takeda, MSD, Janssen, Medpacto, Blueprint medicines, RandBio, Hanmi.<\/b> Other, Consultancy. <br><b>KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc, J INTS Bio, Therapex Co., Ltd, Gilead, Amgen<\/b> Other, Advisory boards. <br><b>ASCO, AstraZeneca, Guardant, Roche, ESMO, IASLC, Korean Cancer Association, Korean Society of Medical Oncology, Korean Society of Thyroid-Head and Neck Surgery, Korean Cancer Study Group<\/b> Other, Invited speaker. <br><b>Novartis, MSD, The Chinese Thoracic Oncology Society, Pfizer<\/b> Other, Invited speaker. <br><b>TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO<\/b> Stock, Other, Stocks\/shares. <br><b>DAAN Biotherapeutics<\/b> Founder. <br><b>J INTS BIO<\/b> Other, Member of the board of directors. <br><b>T. Cs&#337;szi, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Study support to institution and funding for medical writing assistance. <br><b>T. Shentzer Kutiel, <\/b> <br><b>Bristol-Myers Squibb, MSD, Merck KGaA \/ Merck Serono<\/b> Other, Honoraria. <br><b>V. Müller, <\/b> <br><b>MSD, Roche, AstraZeneca, Boehringer-Ingelheim, Pfizer.<\/b> Other, Lectures and advisory boards. <br><b>M. Ahn, <\/b> <br><b>AstraZeneca, BMS, MSD, Lilly, Merck KGaA \/ Merck Serono \/ Merck Biopharma, ONO, Roche, Takeda, Yuhan, Amgen.<\/b> Other, Honoraria. <br><b>AstraZeneca, BMS, ONO, Takeda, Lilly, Merck KGaA \/ Merck Serono \/ Merck Biopharma, MSD, Amgen, Novartis, Roche, Yuhan, Arcus, Pfizer, Daichi-Sankyo, Alpha pharmaceutical, Voronoi, Eutilex<\/b> Other, Consultant or Advisor. <br><b>D. Kowalski, <\/b> <br><b>MSD, Pfizer, Amgen, BMS, AstraZeneca, Sanofi-Aventis, Boehringer-Ingelheim, Takeda, Roche, Novartis, Johnson & Johnson, Merck KGaA.<\/b> Other, Advisory Board and consultancy. <br><b>M. Maio, <\/b> <br><b>Roche; Bristol Myers Squibb; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Incyte; AstraZeneca; Amgen; Pierre Fabre; Eli Lilly; GlaxoSmithKline; Sanofi; Alfasigma<\/b> Other, Advisor\/board member. <br><b>Merck Serono<\/b> Other, Advisor\/board member, Honoraria. <br><b>Roche, Bristol Myers Squibb; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; AstraZeneca; Amgen; Pierre Fabre; Eli Lilly; GlaxoSmithKline; Sciclone; Sanofi; Alfasigma<\/b> Other, Honoraria. <br><b>Epigen Therapeutics, and Theravance<\/b> Stock. <br><b>V. Moiseyenko, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Study funding to the institution. <br><b>A. Navarro, <\/b> <br><b>Bristol-Myers Squibb, F. Hoffmann La Roche AG, Pfizer, Boehringer Ingelheim, Oryzon Genomics, AstraZeneca, Hengenix, Amgen, Adium Pharma, Eczacibasi Pharmaceuticals<\/b> Other, Advisory role, speaker’s bureau or travel compensation. <br><b>J. Niu, <\/b> <br><b>AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Mirati Therapeutics, Takeda, Sanofi, Pfizer, G1 Therapeutics<\/b> Other, Consulting and Advisory role. <br><b>A. S. Fung, <\/b> <br><b>Novartis<\/b> Other, Advisory board. <br><b>AstraZeneca<\/b> Other, Research funding to institute. <br><b>C. Lips, <\/b> <br><b>Roche, Novartis, AstraZeneca, BMS, Sanofi<\/b> Other, Consulting and Advisory Board. <br><b>H. Zhou, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>B. Zhao, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>H. Lara-Guerra, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>N. Peled, <\/b> <br><b>AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, Guardant360, Imagene, Merck KGaA, MSD, Novartis, Novocure, Pfizer, Roche, Renium, Takeda<\/b> Other, Advisor & Honorarium from & Research.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11574","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT253","PresenterBiography":null,"PresenterDisplayName":"Delvys Rodríguez Abreu, MD;PhD","PresenterKey":"7710d6ca-d67c-41c5-b3f1-f201680d6085","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT253. Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Lung cancer: small cell,Immunotherapy,T cell,limited stage,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Gong<\/b><sup>1<\/sup>, Q. Pang<sup>2<\/sup>, R. Yu<sup>3<\/sup>, Z. Zhu<sup>4<\/sup>, J. Huang<sup>5<\/sup>, Y. Cheng<sup>6<\/sup>, D. Zhong<sup>7<\/sup>, H. Wu<sup>8<\/sup>, S. Yoo<sup>9<\/sup>, T. Dobbs<sup>10<\/sup>, Z. Bao<sup>11<\/sup>, Y. Zuo<sup>11<\/sup>, B. Wei<sup>12<\/sup>, P. Sun<sup>11<\/sup>, Y. Lu<sup>1<\/sup>; <br\/><sup>1<\/sup>West China Hospital, Sichuan University, Chengdu, China, <sup>2<\/sup>Tianjin Medical University Cancer Institute & Hospital, Tianjin, China, <sup>3<\/sup>Beijing Cancer Hospital, Beijing, China, <sup>4<\/sup>Fudan University Shanghai Cancer Center, Shanghai, China, <sup>5<\/sup>Medical University Affiliated Tumor Hospital, Guangxi, China, <sup>6<\/sup>Qilu Hospital of Shandong University, Jinan, China, <sup>7<\/sup>Tianjin Medical University General Hospital, Tianjin, China, <sup>8<\/sup>Henna Cancer Hospital, Zhengzhou, China, <sup>9<\/sup>Kyungpook National University Hospital, Daegu, Korea, Republic of, <sup>10<\/sup>Tennessee Cancer Specialist, Knoxville, TN, <sup>11<\/sup>BeiGene (Shanghai) Co., Ltd., Shanghai, China, <sup>12<\/sup>BeiGene (Beijing) Co., Ltd., Beijing, China","CSlideId":"","ControlKey":"07b17f6c-fed5-4312-9d99-052b1cdd3ee5","ControlNumber":"9894","DisclosureBlock":"&nbsp;<b>Y. Gong, <\/b> None..<br><b>Q. Pang, <\/b> None..<br><b>R. Yu, <\/b> None..<br><b>Z. Zhu, <\/b> None..<br><b>J. Huang, <\/b> None..<br><b>Y. Cheng, <\/b> None..<br><b>D. Zhong, <\/b> None..<br><b>H. Wu, <\/b> None..<br><b>S. Yoo, <\/b> None..<br><b>T. Dobbs, <\/b> None.&nbsp;<br><b>Z. Bao, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>Y. Zuo, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option. <br><b>B. Wei, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>P. Sun, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>Y. Lu, <\/b> <br><b>BeiGene<\/b> Independent Contractor. <br><b>Roche\/ Genentec<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Independent Contractor. <br><b>Bristol-Myers Squibb<\/b> Grant\/Contract. <br><b>Merck Sharp & Dohme<\/b> Grant\/Contract.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11576","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT255","PresenterBiography":"","PresenterDisplayName":"Kayla Hayes, BA","PresenterKey":"aa2be8be-745d-491a-8832-1ceb669bcfcd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT255. AdvanTIG-204:<b> <\/b>A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"AdvanTIG-204:<b> <\/b>A phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Pembrolizumab,PD-1,PD-L1,Immunotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Alejandro Navarro<sup>1<\/sup>, Myung-Ju Ahn<sup>2<\/sup>, James Stevenson<sup>3<\/sup>, Nir Peled<sup>4<\/sup>, Talia Shentzer Kutiel<sup>5<\/sup>, Florian Huemer<sup>6<\/sup>, Dong-Wan Kim<sup>7<\/sup>, Maria Jove Casulleras<sup>8<\/sup>, Adnan Khattak<sup>9<\/sup>, Dariusz Kowalski<sup>10<\/sup>, Natasha B. Leighl<sup>11<\/sup>, Filippo de Marinis<sup>12<\/sup>, Carolin Lips<sup>13<\/sup>, Jiaxin Niu<sup>14<\/sup>, Mo Huang<sup>15<\/sup>, Bin Zhao<sup>15<\/sup>, <b>Hazem El-Osta<\/b><sup>15<\/sup>, Taofeek Owonikoko<sup>16<\/sup><br><br\/><sup>1<\/sup>Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain,<sup>2<\/sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of,<sup>3<\/sup>Cleveland Clinic, Cleveland, OH,<sup>4<\/sup>Shaare Zedek Medical Center, Jerusalem, Israel,<sup>5<\/sup>Rambam Health Care Campus, Haifa, Israel,<sup>6<\/sup>LBI for Lung Health, Klinik Penzing, Vienna, Austria,<sup>7<\/sup>Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea, Republic of,<sup>8<\/sup>Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Barcelona, Spain,<sup>9<\/sup>Hollywood Private Hospital and Edith Cowan University, Perth, WA, Australia,<sup>10<\/sup>Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland,<sup>11<\/sup>Princess Margaret Cancer Center, Toronto, ON, Canada,<sup>12<\/sup>Istituto Europeo di Oncologia, Milan, Italy,<sup>13<\/sup>Kantonsspital St.Gallen, Department of Medical Oncology, St. Gallen, Switzerland,<sup>14<\/sup>Banner MD Anderson, Gilbert, AZ,<sup>15<\/sup>Merck & Co., Inc., Rahway, NJ,<sup>16<\/sup>University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA","CSlideId":"","ControlKey":"db92b109-f5d7-47c9-a876-2fddafa50045","ControlNumber":"10413","DisclosureBlock":"<b>&nbsp;A. Navarro, <\/b> <br><b>Bristol-Myers Squibb, F. Hoffmann La Roche AG, Pfizer, Boehringer Ingelheim, Oryzon Genomics, AstraZeneca, Hengenix, Amgen, Adium Pharma, Eczacibasi Pharmaceuticals<\/b> Other, Advisory role, speaker’s bureau or travel compensation. <br><b>M. Ahn, <\/b> <br><b>AstraZeneca, BMS, MSD, Lilly, Merck KGaA \/ Merck Serono \/ Merck Biopharma, ONO, Roche, Takeda, YUHAN, Amgen<\/b> Other, Honoraria. <br><b>AstraZeneca, BMS, ONO, Takeda, Lilly, Merck KGaA \/ Merck Serono \/ Merck Biopharma, MSD, Amgen, Novartis, Roche, YUHAN, Arcus, Pfizer, Daichi-Sankyo, Alpha pharmaceutical, Voronoi, Eutilex<\/b> Other, Consultant or Advisor. <br><b>J. Stevenson, <\/b> <br><b>Arcus Biosciences<\/b> Other, Scientific advisory board. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Black Diamond Therapeutics; Alpha Oncology; Amgen<\/b> Other, Research funding to Institution. <br><b>N. Peled, <\/b> <br><b>AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, Guardant360, Imagene, Merck KGaA, MSD, Novartis, Novocure, Pfizer, Roche, Renium, Takeda<\/b> Other, Advisor & Honorarium from & Research with. <br><b>T. Shentzer Kutiel, <\/b> <br><b>Bristol-Myers Squibb, MSD, Merck KGaA \/ Merck Serono<\/b> Other, Honoraria. <br><b>F. Huemer, <\/b> <br><b>Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Janssen, Lilly, Merck Serono, MSD, Roche, Takeda<\/b> Other, Advisory Boards & honoraria. <br><b>D. Kim, <\/b> <br><b>Alpha Biopharma, Amgen, Astrazeneca\/Medimmune, Boehringer-Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi-Sankyo, GSK, Hanmi, InnoN, IQVIA, Janssen<\/b> Other, Research funding to institution. <br><b>Merck KGaA \/ Merck Serono \/ Merck Biopharma, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche\/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan<\/b> Other, Research funding to institution. <br><b>Amgen, AstraZeneca, Boehringer-Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi-Sankyo, GSK, Janssen, Merus, Mirati Therapeutics, MSD, Merck KGaA \/ Merck Serono \/ Merck Biopharma<\/b> Other, Medical writing assistance. <br><b>Novartis, Pfizer, Roche, Takeda, Yuhan<\/b> Other, Medical writing assistance. <br><b>Amgen, AstraZeneca, BMS\/ONO Pharmaceuticals, Daiichi-Sankyo, GSK, Janssen, Merck KGaA \/ Merck Serono \/ Merck Biopharma, MSD, Oncobix, Pfizer, SK Biopharm, Takeda<\/b> Other, Uncompensated consultation or advisory role. <br><b>M. Jove Casulleras, <\/b> <br><b>AstraZeneca, MSD<\/b> Other, Speaker’s bureau. <br><b>MSD, Roche, AstraZeneca<\/b> travel and accommodation support. <br><b>A. Khattak, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, BMS, Merck Serono, Novartis, Moderna<\/b> Other, Speaker honorarium and advisory services. <br><b>D. Kowalski, <\/b> <br><b>Roche, Takeda, AstraZeneca, MSD, BMS, Merck KGaA, Pfizer, Amgen, Johnson & Johnson, Sanofi-Aventis, Boehringer-Ingelheim, Novartis<\/b> Other, Advisory Board & Honorarium. <br><b>N. B. Leighl, <\/b> <br><b>AstraZeneca; Eli Lilly; Inivata; Janssen; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Novartis; Pfizer; Takeda.<\/b> Other, Institutional Grant Funding (University Health Network). <br><b>Beigene; BMS; Janssen; MSD; Novartis; Takeda.<\/b> Other, Honoraria (CME lectures). <br><b>AstraZeneca, Eisai, Janssen, MSD, Sanofi<\/b> Travel, Travel Support (CME lectures). <br><b>F. de Marinis, <\/b> <br><b>AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Roche\/Genentech; Takeda<\/b> Other, Consulting or Advisory Role. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Funding support for study conduct and medical writing. <br><b>C. Lips, <\/b> <br><b>Roche, Novartis, AstraZeneca, BMS, Sanofi<\/b> Other, Consulting and Advisory Board. <br><b>J. Niu, <\/b> <br><b>AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Mirati Therapeutics, Takeda, Sanofi, Pfizer, G1 Therapeutics<\/b> Other, Consulting and Advisory role. <br><b>M. Huang, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>B. Zhao, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>H. El-Osta, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>T. Owonikoko, <\/b> <br><b>Novartis, Bayer, Regeneron, AstraZeneca, Amgen, Pfizer, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Research Funding (to institution). <br><b>Roche\/Genentech, Cardiff Oncology, Ymabs, Boehringer Ingelheim, Merck Serono<\/b> Other, Research Funding (to institution). <br><b>Novartis, Lilly, Eisai, Bristol-Myers Squibb, Lilly, Amgen, AstraZeneca, Boehringer Ingelheim, Merck Serono, XCovery, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Consulting\/Advisory Board. <br><b>Bayer, Oncocyte, Takeda, Jazz, Zentalis, Ipsen, Daiichi, Janssen, BeiGene, Genentech, Coherus, GenCART, Heat Biologics, Meryx, Puma Biosciences<\/b> Other, Consulting\/Advisory Board. <br><b>Merck Serono, Roche\/Genentech, Takeda<\/b> Other, IRC\/DSMB. <br><b>Coherus Biosciences, GenCART\/Cambium Oncology, Taobob LLC<\/b> Other, Stocks\/Ownership Interest.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11577","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT256","PresenterBiography":null,"PresenterDisplayName":"Hazem El-Osta, MD","PresenterKey":"3b69bc88-1b8a-4ea6-83a7-9e5cd761ba08","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT256. Results from KEYNOTE-B98: A phase 1b\/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer<b> <\/b>(ES-SCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Results from KEYNOTE-B98: A phase 1b\/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer<b> <\/b>(ES-SCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Toxicity,Lung cancer: small cell,Immunotherapy,TGF-&#946;,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. Schroeder<\/b><sup>1<\/sup>, N. Takahashi<sup>1<\/sup>, H. Yang<sup>1<\/sup>, R. Donahue<sup>1<\/sup>, Z. Skidmore<sup>2<\/sup>, A. Konicki<sup>2<\/sup>, M. Nirula<sup>1<\/sup>, M. Greenberg<sup>3<\/sup>, G. Chrisafis<sup>4<\/sup>, Y. Zhang<sup>1<\/sup>, Y.-T. Tsai<sup>1<\/sup>, L. Sciuto<sup>1<\/sup>, S. Nichols<sup>1<\/sup>, M. Abel<sup>1<\/sup>, P. Desai<sup>5<\/sup>, R. Kumar<sup>1<\/sup>, C. Schultz<sup>1<\/sup>, D. Pinkiert<sup>1<\/sup>, C. Graham<sup>1<\/sup>, A. Sharma<sup>1<\/sup>, J. Malin<sup>1<\/sup>, M. Krishnamurthy<sup>6<\/sup>, S. Zhuang<sup>1<\/sup>, M. Lee<sup>1<\/sup>, L. Rinaldi<sup>2<\/sup>, J. Schlom<sup>1<\/sup>, L. Wakefield<sup>1<\/sup>, A. Thomas<sup>1<\/sup>; <br\/><sup>1<\/sup>National Institutes of Health, Bethesda, MD, <sup>2<\/sup>Delfi Diagnostics, Baltimore, MD, <sup>3<\/sup>Penn State Medical Center, Hershey, PA, <sup>4<\/sup>Wake Forrest Medical Center, Winston-Salem, NC, <sup>5<\/sup>Fox Chase Cancer Center, Philadelphia, PA, <sup>6<\/sup>Mount Sinai Hospital, New York, NY","CSlideId":"","ControlKey":"4429828a-f909-4c3e-a125-5fa106485f69","ControlNumber":"10767","DisclosureBlock":"&nbsp;<b>B. Schroeder, <\/b> None..<br><b>N. Takahashi, <\/b> None..<br><b>H. Yang, <\/b> None..<br><b>R. Donahue, <\/b> None..<br><b>Z. Skidmore, <\/b> None..<br><b>A. Konicki, <\/b> None..<br><b>M. Nirula, <\/b> None..<br><b>M. Greenberg, <\/b> None..<br><b>G. Chrisafis, <\/b> None..<br><b>Y. Zhang, <\/b> None..<br><b>Y. Tsai, <\/b> None..<br><b>L. Sciuto, <\/b> None..<br><b>S. Nichols, <\/b> None..<br><b>M. Abel, <\/b> None..<br><b>P. Desai, <\/b> None..<br><b>R. Kumar, <\/b> None..<br><b>C. Schultz, <\/b> None..<br><b>D. Pinkiert, <\/b> None..<br><b>C. Graham, <\/b> None..<br><b>A. Sharma, <\/b> None..<br><b>J. Malin, <\/b> None..<br><b>M. Krishnamurthy, <\/b> None..<br><b>S. Zhuang, <\/b> None..<br><b>M. Lee, <\/b> None..<br><b>L. Rinaldi, <\/b> None..<br><b>J. Schlom, <\/b> None..<br><b>L. Wakefield, <\/b> None..<br><b>A. Thomas, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11578","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT257","PresenterBiography":null,"PresenterDisplayName":"Brett Schroeder, MD","PresenterKey":"f2a760ef-c58a-4b0a-aa90-577d5e385353","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT257. Hyperprogressive disease following bintrafusp alfa and DNA damaging chemotherapy in relapsed small cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Hyperprogressive disease following bintrafusp alfa and DNA damaging chemotherapy in relapsed small cell lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Immune checkpoint blockade,Microbiome,Melanoma\/skin cancers,Fecal Microbiota Transplantation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Duttagupta<\/b><sup>1<\/sup>, M. Messaoudene<sup>1<\/sup>, R. Jamal<sup>1<\/sup>, C. Mihalcioiu<sup>2<\/sup>, K. Belanger<sup>1<\/sup>, J. Lenehan<sup>3<\/sup>, W. Belkaid<sup>1<\/sup>, S. N. Parvathy<sup>3<\/sup>, J. Maillou<sup>1<\/sup>, Y. Hu<sup>1<\/sup>, M. Ponce<sup>1<\/sup>, T. Hakozaki<sup>1<\/sup>, E. M. Salazar<sup>1<\/sup>, M. Silverman<sup>3<\/sup>, S. M. Vareki<sup>3<\/sup>, A. Elkrief<sup>1<\/sup>, B. Routy<sup>1<\/sup>; <br\/><sup>1<\/sup>Research Center of the Centre Hospitalier de l’Université de Montréal(CRCHUM), Montreal, QC, Canada, <sup>2<\/sup>McGill University Health Centre, Montreal, QC, Canada, <sup>3<\/sup>Western University, London, ON, Canada","CSlideId":"","ControlKey":"2e913a98-79bf-4e40-9c7e-df48824d5cad","ControlNumber":"10818","DisclosureBlock":"&nbsp;<b>S. Duttagupta, <\/b> None..<br><b>M. Messaoudene, <\/b> None..<br><b>R. Jamal, <\/b> None..<br><b>C. Mihalcioiu, <\/b> None..<br><b>K. Belanger, <\/b> None..<br><b>J. Lenehan, <\/b> None..<br><b>W. Belkaid, <\/b> None..<br><b>S. N. Parvathy, <\/b> None..<br><b>J. Maillou, <\/b> None..<br><b>Y. Hu, <\/b> None..<br><b>M. Ponce, <\/b> None..<br><b>T. Hakozaki, <\/b> None..<br><b>E. M. Salazar, <\/b> None..<br><b>M. Silverman, <\/b> None..<br><b>S. M. Vareki, <\/b> None..<br><b>A. Elkrief, <\/b> None.&nbsp;<br><b>B. Routy, <\/b> <br><b>Science Curebiota<\/b> Other, Co founder. <br><b>Kaleido<\/b> Grant\/Contract. <br><b>Vedanta<\/b> Grant\/Contract. <br><b>Da Volterra<\/b> Grant\/Contract. <br><b>Surface<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Other, Consultant. <br><b>AstraZeneca<\/b> Other, Consultant. <br><b>Merck<\/b> Other, Consultant. <br><b>Da Volterra<\/b> Other, Consultant.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11579","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT258","PresenterBiography":null,"PresenterDisplayName":"Sreya Duttagupta","PresenterKey":"f46d16c8-eb49-41f8-b519-d9fa9d333ea0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT258. Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Interleukin-2,Immunotherapy,Immuno-oncology,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"V. G. Atkinson<sup>1<\/sup>, J. F. Antras<sup>2<\/sup>, P. Bedard<sup>2<\/sup>, W. Brenner<sup>3<\/sup>, J. Brown<sup>4<\/sup>, C. R. Lemech<sup>5<\/sup>, P. Lloyd<sup>6<\/sup>, K. Margolin<sup>7<\/sup>, M. Mathew<sup>3<\/sup>, J. J. Park<sup>8<\/sup>, S. Thomas<sup>9<\/sup>, P. Twardowski<sup>7<\/sup>, H. Gardner<sup>10<\/sup>, A. Prawira<sup>11<\/sup>, M. Coello<sup>10<\/sup>, W. Ebrahimimizadeh<sup>10<\/sup>, M. D. To<sup>10<\/sup>, R. Merchant<sup>10<\/sup>, S. Madduri Karanam<sup>10<\/sup>, A. Yavari<sup>12<\/sup>, L. L. Siu<sup>2<\/sup>, H. A. Tawbi<sup>13<\/sup>, <b>P. A. Ascierto<\/b><sup>14<\/sup>; <br\/><sup>1<\/sup>Princess Alexandra Hospital, Woolloongabba, Australia, <sup>2<\/sup>Princess Margaret Hospital, Toronto, ON, Canada, <sup>3<\/sup>Boca Raton Regional Hospital, Boca Raton, FL, <sup>4<\/sup>Emory Cancer Institute, Atlanta, FL, <sup>5<\/sup>Scientia Clinical Research, Sydney, Australia, <sup>6<\/sup>KinDyn Consulting Ltd, London, United Kingdom, <sup>7<\/sup>Saint John’s Cancer Institute, Santa Monica, CA, <sup>8<\/sup>Macquarie University, Sydney, Australia, <sup>9<\/sup>Orlando Health Cancer Institute, Orlando, FL, <sup>10<\/sup>Medicenna Therapeutics, Toronto, ON, Canada, <sup>11<\/sup>Obatica Pty Ltd, Sydney, Australia, <sup>12<\/sup>Radcliffe Department of Medicine, Oxford, United Kingdom, <sup>13<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX, <sup>14<\/sup>Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy","CSlideId":"","ControlKey":"962284d0-9ba4-4470-a32b-8c876150a3e7","ControlNumber":"10811","DisclosureBlock":"<b>&nbsp;V. G. Atkinson, <\/b> <br><b>Bristol Myers Squibb<\/b> Independent Contractor, Travel. <br><b>Merck Sharp & Dohme<\/b> Independent Contractor, Travel. <br><b>Novartis<\/b> Independent Contractor, Travel. <br><b>Merck Serono<\/b> Independent Contractor. <br><b>Q Biotics<\/b> Independent Contractor. <br><b>Immunocore<\/b> Independent Contractor. <br><b>Pierre Fabre<\/b> Travel. <br><b>Nektar<\/b> Other, Honoraria. <br><b>Provectus Biopharmaceuticals<\/b> Other, Honoraria.<br><b>J. F. Antras, <\/b> None.&nbsp;<br><b>P. Bedard, <\/b> <br><b>BMS<\/b> Other, Institution consulting and grants. <br><b>Pfizer<\/b> Other, Institution consulting. <br><b>Seagen<\/b> Independent Contractor. <br><b>Lilly<\/b> Independent Contractor, Other, Institution consulting and grants. <br><b>Amgen<\/b> Independent Contractor, Other, Institution consulting and grants. <br><b>Merck<\/b> Independent Contractor, Institution consulting and grants. <br><b>Gilead Sciences<\/b> Independent Contractor, Other, Institution consulting and grants. <br><b>Zymworks<\/b> Independent Contractor, Other, Institution consulting and grants. <br><b>Repare Therapeutics<\/b> Independent Contractor. <br><b>Janssen Oncology<\/b> Independent Contractor. <br><b>Genetech<\/b> Other, Institution consulting and grants. <br><b>GSK<\/b> Other, Institution consulting and grants. <br><b>Novartis<\/b> Other, Institution consulting and grants. <br><b>Bicara Therapeutics<\/b> Other, Institution consulting and grants. <br><b>Medicenna Therapeutics<\/b> Other, Institution consulting and grants. <br><b>Bayer<\/b> Other, Institution consulting and grants. <br><b>Takeda<\/b> Other, Institution consulting and grants. <br><b>LegoChem Biosciences<\/b> Other, Institution consulting and grants.<br><b>W. Brenner, <\/b> None..<br><b>J. Brown, <\/b> None..<br><b>C. R. Lemech, <\/b> None.&nbsp;<br><b>P. Lloyd, <\/b> <br><b>Medicenna Therapeutics<\/b> Independent Contractor. <br><b>K. Margolin, <\/b> <br><b>ImaginAb<\/b> Other, Advisory. <br><b>Iovance<\/b> Other, Advisory. <br><b>Werewolf<\/b> Other, Advisory. <br><b>Tentarix Biotherapeutics<\/b> Other, Advisory. <br><b>Xilio<\/b> Other, Advisory. <br><b>Natera<\/b> Other, Advisory. <br><b>Elicio<\/b> Other, Advisory. <br><b>Lilly<\/b> Other, Honorarium. <br><b>AstraZeneca<\/b> Other, Honorarium. <br><b>M. Mathew, <\/b> <br><b>Navinta<\/b> Stock. <br><b>CorMedix<\/b> Stock.<br><b>J. J. Park, <\/b> None.&nbsp;<br><b>S. Thomas, <\/b> <br><b>BMS<\/b> Other, Speakers Bureau. <br><b>Merck<\/b> Other, Speakers Bureau. <br><b>Genentech<\/b> Other, Speakers Bureau. <br><b>Ipsen<\/b> Other, Speakers Bureau. <br><b>Amgen<\/b> Other, Speakers Bureau. <br><b>Pfizer<\/b> Other, Speakers Bureau. <br><b>Novartis<\/b> Other, Speakers Bureau. <br><b>Natera<\/b> Other, Speakers Bureau. <br><b>P. Twardowski, <\/b> <br><b>Sanofi<\/b> Other, Advisory, Speaker Bureau. <br><b>Janssen<\/b> Other, Advisory, Speaker Bureau, Honorarium. <br><b>AstraZeneca<\/b> Other, Advisory, Speaker Bureau, Honorarium. <br><b>Astellas Pharma<\/b> Other, Speaker Bureau, Honorarium. <br><b>Bayer<\/b> Speaker Bureau, Honorarium. <br><b>Genentech<\/b> Other, Speaker Bureau, Honorarium. <br><b>AVEO<\/b> Other, Honorarium. <br><b>Pfizer<\/b> Other, Honorarium. <br><b>Merck<\/b> Other, Honorarium. <br><b>BMS\/Medarex<\/b> Other, Honorarium. <br><b>H. Gardner, <\/b> <br><b>Medicenna Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>A. Prawira, <\/b> <br><b>Novatech<\/b> Other, Honoraria. <br><b>Medicenna Therapeutics<\/b> Independent Contractor. <br><b>Obatica Pty Ltd<\/b> Employment. <br><b>M. Coello, <\/b> <br><b>Medicenna Therapeutics<\/b> Employment, Stock Option. <br><b>W. Ebrahimimizadeh, <\/b> <br><b>Medicenna Therapeutics<\/b> Employment, Stock Option. <br><b>M. D. To, <\/b> <br><b>Medicenna Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>Northern Biologics<\/b> Other Securities. <br><b>R. Merchant, <\/b> <br><b>Medicenna Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. Madduri Karanam, <\/b> <br><b>Medicenna Therapeutics<\/b> Employment, Stock Option. <br><b>A. Yavari, <\/b> <br><b>Weathrden<\/b> Employment. <br><b>Medicenna Therapeutics<\/b> Other, consultant. <br><b>Imbria Pharmaceuticals<\/b> Stock. <br><b>Sbi Pharmaceuticals<\/b> Grant\/Contract. <br><b>L. L. Siu, <\/b> <br><b>Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Navire, Relay, Daiichi Sankyo, Amgen, Marengo, Medicenna, Tubulis, LTZ Therapeutics, Pangea<\/b> Other, Advisory Board. <br><b>Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche\/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Mirati, BioNTech, 23Me, EMD Serono<\/b> Grant\/Contract. <br><b>Agios<\/b> Stock. <br><b>Treadwell Therapeutics<\/b> Other Business Ownership. <br><b>H. A. Tawbi, <\/b> <br><b>Medicenna Therapeutics<\/b> Other, Advisory Board. <br><b>Novartis<\/b> Other, Advisory Board\/Institution Funding. <br><b>BMS<\/b> Other, Advisory Board\/Institution Funding. <br><b>Genentech<\/b> Other, Advisory Board\/Institution Funding. <br><b>Merck<\/b> Other, Advisory Board\/Institution Funding. <br><b>Eisai<\/b> Other, Advisory Board. <br><b>Iovance Biotherapeutics<\/b> Other, Advisory Board. <br><b>Karyopharm Therapeutics<\/b> Other, Advisory Board. <br><b>Boxer Capital<\/b> Other, Advisory Board. <br><b>Jazz Pharmaceutical<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Other, Advisory Board. <br><b>GSK<\/b> Institution Funding. <br><b>Cellgene<\/b> Other, Institution Funding. <br><b>Dragonfly Therapeutics<\/b> Other, Institution Funding. <br><b>RAPT Therapeutics<\/b> Other, Institution Funding. <br><b>P. A. Ascierto, <\/b> <br><b>BMS, Medicenna Therapeutic, Roche, MSD, Novartis, Merck Serrono, Pierre Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, ImmunoCore, 4SC, Italfarmaco, Nektar, BI, Eisai, Regeneron,<\/b> Other, Advisory Board. <br><b>Daiichi Sankyop, Pfizer, OncoSec. Nouscom, Lunaphore Technologies, Seagen, Iteos Therapeutics, Bio-AI Health, Valo Tx, Replimune, Bayer, Erasca Inc, Philogen, BioNTech, Anaveon<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Grant\/Contract, Travel. <br><b>Bio AI Health<\/b> Travel. <br><b>Repimmune<\/b> Travel. <br><b>MSD Oncology<\/b> Travel. <br><b>Peirre Fabre<\/b> Travel. <br><b>BMS<\/b> Grant\/Contract. <br><b>Roche\/Genentech<\/b> Grant\/Contract. <br><b>Sanofi<\/b> Grant\/Contract.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11580","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT259","PresenterBiography":null,"PresenterDisplayName":"Paolo Ascierto, MD","PresenterKey":"08a44d44-ebee-4cd7-b56d-b03ce8fd88bd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT259. Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1\/2 trial show evidence of single-agent activity in advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1\/2 trial show evidence of single-agent activity in advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Uveal melanoma,Focal adhesion kinase (FAK),MEK inhibitor,Melanoma\/skin cancers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Rino S. Seedor<\/b><sup>1<\/sup>, Mizue Terai<sup>1<\/sup>, Amry Majeed<sup>1<\/sup>, Ryota Tanaka<sup>1<\/sup>, Andrew  E.  Aplin<sup>1<\/sup>, Marlana Orloff<sup>1<\/sup>, Alfredo  A.  Molinolo<sup>2<\/sup>,  J.  Silvio Gutkind<sup>2<\/sup>, Takami Sato<sup>1<\/sup><br><br\/><sup>1<\/sup>Jefferson Health Sidney Kimmel Cancer Center, Philadelphia, PA,<sup>2<\/sup>Moores Cancer Center, University of California San Diego, San Diego, CA","CSlideId":"","ControlKey":"575f57c2-886f-4f66-986f-bb9ff595a584","ControlNumber":"9767","DisclosureBlock":"&nbsp;<b>R. S. Seedor, <\/b> None..<br><b>M. Terai, <\/b> None..<br><b>A. Majeed, <\/b> None..<br><b>R. Tanaka, <\/b> None..<br><b>A. E. Aplin, <\/b> None.&nbsp;<br><b>M. Orloff, <\/b> <br><b>Immunocore<\/b> Other, Consultant and Speaker. <br><b>Replimune<\/b> Other, Consultant. <br><b>IDEAYA<\/b> Other, Steering committee member.<br><b>A. A. Molinolo, <\/b> None.&nbsp;<br><b>J. S. Gutkind, <\/b> <br><b>Domain Therapeutics<\/b> Other, Consultant and Scientific Advisory Board Meeting Member. <br><b>Pangea Theraupeutics Ltd<\/b> Other, Consultant and Scientific Advisory Board Meeting Member. <br><b>I09 LLC<\/b> Other, Consultant. <br><b>Ono Pharma USA<\/b> Other, Consultant. <br><b>Kadima Pharmaceuticals<\/b> Other Business Ownership, Founder. <br><b>Verastem Oncology, Inc<\/b> Other, Institutional Lab Service Agreement. <br><b>Springworks Therapeutics<\/b> Other, Institutional Lab Service Agreement.<br><b>T. Sato, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11581","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT260","PresenterBiography":null,"PresenterDisplayName":"Rino Seedor, MD","PresenterKey":"c461f3d1-8e02-43d2-ba85-69650bf5d2b0","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT260. A phase II trial of defactinib combined with avutometinib in patients with metastatic uveal melanoma<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase II trial of defactinib combined with avutometinib in patients with metastatic uveal melanoma<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Melanoma\/skin cancers,Checkpoint Inhibitors,PARP inhibitors,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Isaacs<\/b><sup>1<\/sup>, T. A. Sussman<sup>1<\/sup>, L. B. Kennedy<sup>1<\/sup>, J. Arbesman<sup>1<\/sup>, B. Gastman<sup>1<\/sup>, M. Zhou<sup>2<\/sup>, E. Zabor<sup>1<\/sup>, C. Diaz-Montero<sup>1<\/sup>, J. Ko<sup>1<\/sup>, P. Funchain<sup>3<\/sup>; <br\/><sup>1<\/sup>Cleveland Clinic, Cleveland, OH, <sup>2<\/sup>Case Western Reserve University, Cleveland, OH, <sup>3<\/sup>Stanford University, Palo Alto, CA","CSlideId":"","ControlKey":"5275f6dd-ba45-4a4f-9b05-5551dd988b95","ControlNumber":"9753","DisclosureBlock":"&nbsp;<b>J. Isaacs, <\/b> None.&nbsp;<br><b>T. A. Sussman, <\/b> <br><b>Pfizer<\/b> Other, Consulting.<br><b>L. B. Kennedy, <\/b> None.&nbsp;<br><b>J. Arbesman, <\/b> <br><b>Castle Biosciences<\/b> Grant\/Contract. <br><b>Variant Bio<\/b> Grant\/Contract. <br><b>B. Gastman, <\/b> <br><b>Iovance<\/b> Employment.<br><b>M. Zhou, <\/b> None..<br><b>E. Zabor, <\/b> None..<br><b>C. Diaz-Montero, <\/b> None..<br><b>J. Ko, <\/b> None.&nbsp;<br><b>P. Funchain, <\/b> <br><b>Pfizer<\/b> Grant\/Contract. <br><b>BMS<\/b> Grant\/Contract, Other, Consulting. <br><b>Taiho<\/b> Grant\/Contract. <br><b>Merck<\/b> Other, Consulting. <br><b>GigaGen<\/b> Other, Consulting. <br><b>Eisai<\/b> Other, Consulting. <br><b>Novartis<\/b> Other, Consulting. <br><b>Array<\/b> Other, Consulting. <br><b>Hexal AG<\/b> Other, Consulting. <br><b>Nirvana Healthcare Ventures<\/b> Other, Advisory.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11582","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT261","PresenterBiography":null,"PresenterDisplayName":"James Isaacs, MD","PresenterKey":"8d83f0cf-4e68-4b5c-9342-89a09fdfce3d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT261. Phase II trial of nivolumab in combination with talazoparib in patients with unresectable or metastatic melanoma and mutations in <i>BRCA <\/i>or <i>BRCA<\/i>-ness","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase II trial of nivolumab in combination with talazoparib in patients with unresectable or metastatic melanoma and mutations in <i>BRCA <\/i>or <i>BRCA<\/i>-ness","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Ipilimumab,Nivolumab,DART,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Chae<\/b><sup>1<\/sup>, M. Othus<sup>2<\/sup>, S. Patel<sup>3<\/sup>, P. Sandhu<sup>4<\/sup>, L. R. Corum<sup>5<\/sup>, J. P. Cetnar<sup>6<\/sup>, S. Rayani<sup>7<\/sup>, A. Moseley<sup>2<\/sup>, L.-Y. Chung<sup>1<\/sup>, H. Kim<sup>1<\/sup>, C. M. McLeod<sup>8<\/sup>, H. X. Chen<sup>9<\/sup>, E. Sharon<sup>10<\/sup>, H. Streicher<sup>9<\/sup>, C. W. Ryan<sup>6<\/sup>, C. D. Blanke<sup>11<\/sup>, R. Kurzrock<sup>12<\/sup>; <br\/><sup>1<\/sup>Northwestern Univ. Feinberg School of Medicine, Chicago, IL, <sup>2<\/sup>SWOG Statistics and Data Management Center, Seattle, WA, <sup>3<\/sup>University of California at San Diego Moores Cancer Center, La Jolla, CA, <sup>4<\/sup>Salina Regional Health Center, Tammy Walker Cancer Center, Salina, KS, <sup>5<\/sup>Olathe Health Cancer Center, Olathe, KS, <sup>6<\/sup>Oregon Health & Science University, Portland, OR, <sup>7<\/sup>University of Chicago, Chicago, IL, <sup>8<\/sup>SWOG Data Operations Center, Seattle, WA, <sup>9<\/sup>National Cancer Institute, Investigational Drug Branch, Cancer Therapy Evaluation Program, Bethesda, MD, <sup>10<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>11<\/sup>SWOG Group Chair’s Office, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, <sup>12<\/sup>Medical College of Wisconsin, Milwaukee, WI","CSlideId":"","ControlKey":"57f9399e-e1ee-49e8-b437-65d00b150a5b","ControlNumber":"10484","DisclosureBlock":"<b>&nbsp;Y. Chae, <\/b> <br><b>Abbvie<\/b> Grant\/Contract. <br><b>BMS<\/b> Grant\/Contract. <br><b>Biodesix<\/b> Grant\/Contract. <br><b>Freenome<\/b> Grant\/Contract. <br><b>Predicine<\/b> Grant\/Contract. <br><b>Roche\/Genentech<\/b> Other, Honoraria\/Advisory Boards. <br><b>AstraZeneca<\/b> Other, Honoraria\/Advisory Boards. <br><b>Foundation Medicine<\/b> Other, Honoraria\/Advisory Boards. <br><b>Neogenomics<\/b> Other, Honoraria\/Advisory Boards. <br><b>Guardant Health<\/b> Other, Honoraria\/Advisory Boards. <br><b>Boehringher Ingelheim<\/b> Other, Honoraria\/Advisory Boards. <br><b>Biodesix<\/b> Other, Honoraria\/Advisory Boards. <br><b>Immuneoncia<\/b> Other, Honoraria\/Advisory Boards. <br><b>Lilly Oncology<\/b> Other, Honoraria\/Advisory Boards. <br><b>Merck<\/b> Other, Honoraria\/Advisory Boards. <br><b>Takeda<\/b> Other, Honoraria\/Advisory Boards. <br><b>Lunit<\/b> Other, Honoraria\/Advisory Boards. <br><b>Jazz Pharmaceutical<\/b> Other, Honoraria\/Advisory Boards. <br><b>Tempus<\/b> Other, Honoraria\/Advisory Boards. <br><b>BMS<\/b> Other, Honoraria\/Advisory Boards. <br><b>M. Othus, <\/b> <br><b>Merck<\/b> Other, Consulting. <br><b>Biosight<\/b> Other, Consulting. <br><b>Celgene<\/b> Other, DSMC. <br><b>Glycomimetcs<\/b> Other, DSMC. <br><b>S. Patel, <\/b> <br><b>Amgen<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board. <br><b>Bristol-Myers Squibb<\/b> Other, Advisory Board. <br><b>Certis<\/b> Other, Advisory Board. <br><b>Eli Lilly<\/b> Other, Advisory Board. <br><b>Jazz<\/b> Other, Advisory Board. <br><b>Genentech<\/b> Other, Advisory Board. <br><b>Illumina<\/b> Other, Advisory Board. <br><b>Merck<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Other, Advisory Board. <br><b>Rakuten<\/b> Other, Advisory Board. <br><b>Tempus<\/b> Other, Advisory Board. <br><b>Fate Therapeutics<\/b> Grant\/Contract. <br><b>Gilead<\/b> Grant\/Contract. <br><b>Iovance<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Roche\/Genentech<\/b> Grant\/Contract. <br><b>SQZ Biotechnologies<\/b> Grant\/Contract.<br><b>P. Sandhu, <\/b> None..<br><b>L. R. Corum, <\/b> None..<br><b>J. P. Cetnar, <\/b> None..<br><b>S. Rayani, <\/b> None..<br><b>A. Moseley, <\/b> None..<br><b>L. Chung, <\/b> None..<br><b>H. Kim, <\/b> None..<br><b>C. M. McLeod, <\/b> None..<br><b>H. X. Chen, <\/b> None..<br><b>E. Sharon, <\/b> None..<br><b>H. Streicher, <\/b> None.&nbsp;<br><b>C. W. Ryan, <\/b> <br><b>Ayala<\/b> Grant\/Contract. <br><b>Bayer<\/b> Grant\/Contract. <br><b>Bristol Myers Squib<\/b> Grant\/Contract. <br><b>Daiichi<\/b> Grant\/Contract. <br><b>Deciphera<\/b> Grant\/Contract. <br><b>Exelexis<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>GSK<\/b> Grant\/Contract. <br><b>Karyopharm<\/b> Grant\/Contract. <br><b>Leducq<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Nektar<\/b> Grant\/Contract. <br><b>OSI<\/b> Grant\/Contract. <br><b>PF Argentum IP Holdings LLC<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Rain Therapeutics<\/b> Grant\/Contract. <br><b>Shasqi<\/b> Grant\/Contract. <br><b>Xynomic<\/b> Grant\/Contract.<br><b>C. D. Blanke, <\/b> None.&nbsp;<br><b>R. Kurzrock, <\/b> <br><b>Boehringer Ingelheim<\/b> Grant\/Contract. <br><b>Debiopharm<\/b> Grant\/Contract. <br><b>Foundation Medicine<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Grifols<\/b> Grant\/Contract. <br><b>Guardant<\/b> Grant\/Contract. <br><b>Incyte<\/b> Grant\/Contract. <br><b>Konica Minolta<\/b> Grant\/Contract. <br><b>Medimmune<\/b> Grant\/Contract. <br><b>Merck Serono<\/b> Grant\/Contract. <br><b>Omniseq<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Sequenom<\/b> Grant\/Contract. <br><b>Takeda<\/b> Grant\/Contract. <br><b>TopAlliance<\/b> Grant\/Contract. <br><b>Actuate Therapeutics<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board. <br><b>Bicara Therapeutics, Inc.<\/b> Other, Advisory Board. <br><b>Biological Dynamics<\/b> Other, Advisory Board. <br><b>Caris<\/b> Other, Advisory Board.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11583","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT262","PresenterBiography":null,"PresenterDisplayName":"Young Kwang Chae, MBA;MD;MPH","PresenterKey":"8df399ee-0bd8-47fc-9531-5e39df421ecc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT262. <b><u>A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: sarcomatoid carcinoma of lung (cohort 11)<\/u><\/b><b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"<b><u>A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: sarcomatoid carcinoma of lung (cohort 11)<\/u><\/b><b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Immuno-oncology,Immune checkpoint blockade,Pharmacodynamics,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K. V. Ferry-Galow<\/b><sup>1<\/sup>, K. K. Fino<sup>2<\/sup>, G. O'Sullivan Coyne<sup>3<\/sup>, N. Moore<sup>3<\/sup>, E. Sharon<sup>4<\/sup>, M. Burgess<sup>5<\/sup>, J. Chen<sup>6<\/sup>, A. P. Conley<sup>7<\/sup>, E. J. Davis<sup>8<\/sup>, P. Merriam<sup>9<\/sup>, A. R. Abdul Razak<sup>10<\/sup>, B. Van Tine<sup>11<\/sup>, J. C. Foster<sup>4<\/sup>, N. Takebe<sup>12<\/sup>, C. L. Rosenberger<sup>12<\/sup>, J. H. Doroshow<sup>12<\/sup>, A. P. Chen<sup>3<\/sup>, R. E. Parchment<sup>2<\/sup>; <br\/><sup>1<\/sup>Clinical Pharmacodynamics Biomarkers Program, Applied\/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, <sup>2<\/sup>Clinical Pharmacodynamic Biomarkers Program, Applied\/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, <sup>3<\/sup>Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, <sup>4<\/sup>Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, <sup>5<\/sup>University of Pittsburg Medical Center Hillman Cancer Center, Pittsburg, PA, <sup>6<\/sup>Division of Medical Oncology, Dept. of Internal Medicine, The Ohio State University, Columbus, OH, <sup>7<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>8<\/sup>Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, <sup>9<\/sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, <sup>10<\/sup>Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>11<\/sup>Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, <sup>12<\/sup>Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD","CSlideId":"","ControlKey":"41ddf713-4dc8-4a41-bb46-d57d5c48f17d","ControlNumber":"10734","DisclosureBlock":"&nbsp;<b>K. V. Ferry-Galow, <\/b> None..<br><b>K. K. Fino, <\/b> None..<br><b>G. O'Sullivan Coyne, <\/b> None..<br><b>N. Moore, <\/b> None..<br><b>E. Sharon, <\/b> None.&nbsp;<br><b>M. Burgess, <\/b> <br><b>Merck Sharpe and Dohme<\/b> Grant\/Contract. <br><b>J. Chen, <\/b> <br><b>Tempus<\/b> Employment. <br><b>Patient Matching Algorithm<\/b> Patent. <br><b>A. P. Conley, <\/b> <br><b>Aadi Bioscience<\/b> Independent Contractor. <br><b>Deciphera Pharmaceuticals, Inc.<\/b> Independent Contractor. <br><b>Inhibrx<\/b> Independent Contractor. <br><b>E. J. Davis, <\/b> <br><b>Aadi Bioscience<\/b> Independent Contractor. <br><b>Actuated Medical, Inc.<\/b> Grant\/Contract. <br><b>ADC Therapeutics<\/b> Grant\/Contract. <br><b>bioatla<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb Company<\/b> Grant\/Contract. <br><b>Cogent Therapeutics LLC<\/b> Grant\/Contract. <br><b>Cornerstone<\/b> Grant\/Contract. <br><b>Deciphera Pharmaceuticals, Inc.<\/b> Independent Contractor. <br><b>Genentech USA, Inc.<\/b> Grant\/Contract. <br><b>inhibrx<\/b> Grant\/Contract. <br><b>Karyopharm Therapeutics<\/b> Grant\/Contract. <br><b>MJH Life Sciences<\/b> Independent Contractor. <br><b>top alliance<\/b> Grant\/Contract. <br><b>P. Merriam, <\/b> <br><b>Mereo Biopharma<\/b> Grant\/Contract. <br><b>A. R. Abdul Razak, <\/b> <br><b>AstraZeneca; Deciphera; Karyopharm Therapeutics; Pfizer; Roche\/Genentech; Bristol Myers Squibb; MedImmune; Amgen; GlaxoSmithKline; Blueprint Medicines; Merck; AbbVie; Adaptimmune; Iterion Therapeutic<\/b> Grant\/Contract. <br><b>Medison; GSK; Adaptimmune; Boehringer<\/b> Independent Contractor. <br><b>B. Van Tine, <\/b> <br><b>Acuta Capital Partners; ADRx Advenchen Labs; Apexigen Inc; Ayala Pharma; Bayer Boehringer Ingelheim; Boxer Capital; Cytokinetics Inc; Daiichi Sankyo; Deciphera Pharma<\/b> Independent Contractor. <br><b>EcoR1 Capital; Epizyme, Inc; Iterion Therapeutics, Inc; PTC Therapuetics; Salarius Pharma; Total Health Conference<\/b> Independent Contractor. <br><b>Agenus; Curis; Regeneron Pharmaceuticals<\/b> Other, Data and Safety Monitoring. <br><b>Adaptimmune LLC; Epizyme, Inc.<\/b> Travel. <br><b>GlaxoSmithKline; Merck; Pfizer; Polaris Pharmaceuticals; Tracon Pharmaceuticals<\/b> Grant\/Contract. <br><b>Polaris Pharmaceuticals<\/b> Other, Board Member. <br><b>Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Method<\/b> Other, Licensing Agreements. <br><b>SIGMA-2 RECEPTOR LIGAND DRUG CONJUGATES AS ANTITUMOR COMPOUNDS, METHODS OF SYNTHESIS AND USES THEREOF<\/b> Patent.<br><b>J. C. Foster, <\/b> None..<br><b>N. Takebe, <\/b> None..<br><b>C. L. Rosenberger, <\/b> None.&nbsp;<br><b>J. H. Doroshow, <\/b> <br><b>Design, Production, and Characterization of Human Monoclonal Dual Oxidase (DUOX2) Antibody<\/b> Other Intellectual Property. <br><b>Patent Number: 9,644,037 and 10,738,047 B2<\/b> Patent, Development of a Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in IFA and Other Immunoassays (Patent Number: 9,644,037)\u000d\u000aIodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases; Formulations\/Uses (Patent Number: 10,738,047 B2)\u000d\u000a.<br><b>A. P. Chen, <\/b> None..<br><b>R. E. Parchment, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11584","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT263","PresenterBiography":null,"PresenterDisplayName":"Katherine Ferry-Galow, PhD","PresenterKey":"a905c3a9-1a64-4f53-ba1a-06f69bfd29a2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT263. Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Immune checkpoint blockade,Oncolytic adenovirus,TGF-&#946;,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. P. Conley<\/b><sup>1<\/sup>, T. Reid<sup>2<\/sup>, C. Larson<sup>2<\/sup>, B. Oronsky<sup>2<\/sup>, S. Caroen<sup>2<\/sup>, M. Stirn<sup>2<\/sup>, E. Burbano<sup>2<\/sup>, N. Abrouk<sup>3<\/sup>, C. L. Roland<sup>1<\/sup>, J. Williams<sup>2<\/sup>, L. B. Kennedy<sup>4<\/sup>; <br\/><sup>1<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>EpicentRx, San Diego, CA, <sup>3<\/sup>Clinical Trials Innovations, Mountain View, CA, <sup>4<\/sup>Cleveland Clinic, Cleveland, OH","CSlideId":"","ControlKey":"b2748915-3657-44fa-82d0-b6ffc8173abe","ControlNumber":"10892","DisclosureBlock":"&nbsp;<b>A. P. Conley, <\/b> None.&nbsp;<br><b>T. Reid, <\/b> <br><b>EpicentRx<\/b> Employment, Fiduciary Officer, Stock Option, Patent. <br><b>C. Larson, <\/b> <br><b>EpicentRx<\/b> Employment. <br><b>B. Oronsky, <\/b> <br><b>EpicentRx<\/b> Employment, Stock Option, Patent. <br><b>S. Caroen, <\/b> <br><b>EpicentRx<\/b> Employment, Stock, Patent. <br><b>M. Stirn, <\/b> <br><b>EpicentRx<\/b> Employment, Stock Option. <br><b>E. Burbano, <\/b> <br><b>EpicentRx<\/b> Employment.<br><b>N. Abrouk, <\/b> None..<br><b>C. L. Roland, <\/b> None.&nbsp;<br><b>J. Williams, <\/b> <br><b>EpicentRx<\/b> Employment.<br><b>L. B. Kennedy, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11585","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT264","PresenterBiography":null,"PresenterDisplayName":"Bryan Oronsky, MD","PresenterKey":"81dc60c3-4964-4ed5-81e5-f10ab63718b3","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT264. Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001 +\/- a checkpoint inhibitor","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Improved clinical outcomes in patients received treatment beyond tumor progression with AdAPT-001 +\/- a checkpoint inhibitor","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Targeted therapy,HER2,Biomarkers,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Kim<\/b><sup>1<\/sup>, D. Thomas<sup>2<\/sup>, S. Gadgeel<sup>3<\/sup>, M. Corassa<sup>4<\/sup>, T. J. Tan<sup>5<\/sup>, E. Girda<sup>6<\/sup>, D. Richards<sup>7<\/sup>, S. Tejpar<sup>8<\/sup>, D. Chen<sup>9<\/sup>, J. Fang<sup>10<\/sup>, S. Patel<sup>11<\/sup>, T. R. Wilson<sup>11<\/sup>, F. Barlesi<sup>12<\/sup>; <br\/><sup>1<\/sup>Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>2<\/sup>Centre for Molecular Oncology, University of New South Wales, Sydney, Australia, <sup>3<\/sup>Department of Internal Medicine, Henry Ford Cancer Institute\/Henry Ford Health System, Detroit, MI, <sup>4<\/sup>Medical Oncology Department, AC Camargo Cancer Centre, São Paulo, Brazil, <sup>5<\/sup>Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore, <sup>6<\/sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, <sup>7<\/sup>Texas Oncology, US Oncology Research, Tyler, TX, <sup>8<\/sup>Department of Oncology, Universitair Ziekenhuis Leuven, Leuven, Belgium, <sup>9<\/sup>Genentech, Inc., South San Francisco, CA, <sup>10<\/sup>Hoffmann-La Roche Ltd, Mississauga, Toronto, ON, Canada, <sup>11<\/sup>Genentech Inc., South San Francisco, CA, <sup>12<\/sup>Department of Medical Oncology, International Centre for Thoracic Cancers (CICT), Gustave Roussy, 94805 Villejuif, France; Paris Saclay University, Faculty of Medicine, Kremlin-Bicêtre, France","CSlideId":"","ControlKey":"ecaa7d20-104d-4489-ab06-095d7625eac2","ControlNumber":"9534","DisclosureBlock":"&nbsp;<b>J. Kim, <\/b> None.&nbsp;<br><b>D. Thomas, <\/b> <br><b>Omico UNSW Garvan Institute<\/b> Employment. <br><b>Roche, AstraZeneca, Pfizer, Eisai, Illumina, BeiGene, Elevation Oncology, RedX Pharmaceuticals, SunPharma, Bayer, Abbvie, George Clinical, Janssen, Merck, Kinnate, Microba, BioTessellate<\/b> Other, Consulting or advisory role. <br><b>Omico, NHMRC<\/b> Other, Research funding. <br><b>Roche<\/b> Travel. <br><b>Australian Unity, Foundation Medicine, Guardant, Intervenn, Amgen, Seattle Genetics, Eli Lilly<\/b> Other, Consulting or advisory role. <br><b>S. Gadgeel, <\/b> <br><b>AstraZeneca, Pfizer, Gilead, Boehringer-Ingelheim, Arcus, Blueprint, BMS, Mirati, Genentech\/Roche, Merck, Esai, Eli Lilly, Takeda, GSK<\/b> Other, Consulting or advisory role. <br><b>Mirati, Merck<\/b> Travel. <br><b>M. Corassa, <\/b> <br><b>Roche, MSD, Takeda, AstraZeneca, Janssen<\/b> Other, Consulting or advisory role. <br><b>MSD, Roche, Pfizer, AstraZeneca, Takeda, Eli Lilly, Janssen, Amgen, Novartis, Libbs, BMS.<\/b> Other, Speaker’s Bureau. <br><b>MSD, Roche, AstraZeneca<\/b> Travel. <br><b>T. J. Tan, <\/b> <br><b>AstraZeneca, MSD Oncology<\/b> Other, Honoraria. <br><b>AstraZeneca, Daiichi Sankyo, MSD Oncology, Everest Medicine, Gilead<\/b> Other, Consulting or advisory role. <br><b>AstraZeneca, Bayer, Novartis, AstraZeneca, Seagen, Roche\/Genentech, Daiichi, Sanofi, Eli Lilly<\/b> Other, Research funding. <br><b>Pfizer<\/b> Travel. <br><b>E. Girda, <\/b> <br><b>Merck<\/b> Other, Consulting or Advisory Board. <br><b>D. Richards, <\/b> <br><b>Texas Oncology<\/b> Employment, Other, Leadership. <br><b>Pfizer, Genentech, Jazz, Mirati<\/b> Other, Consulting or advisory role. <br><b>Sarah Cannon Research<\/b> Travel. <br><b>S. Tejpar, <\/b> <br><b>Boehringer Ingelheim<\/b> Other, Consulting or advisory role. <br><b>Boehringer Ingelheim<\/b> Other, Research funding. <br><b>D. Chen, <\/b> <br><b>Genentech<\/b> Employment. <br><b>J. Fang, <\/b> <br><b>Hoffmann-La Roche Ltd<\/b> Employment. <br><b>Yale University<\/b> Consulting or advisory role. <br><b>S. Patel, <\/b> <br><b>Genentech<\/b> Employment. <br><b>T. R. Wilson, <\/b> <br><b>Genentech<\/b> Employment. <br><b>Roche<\/b> Stock. <br><b>F. Barlesi, <\/b> <br><b>AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis<\/b> Other, Institutional financial interests. <br><b>Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, Takeda<\/b> Other, Institutional financial interests.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11586","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"22","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT265","PresenterBiography":null,"PresenterDisplayName":"Helen Miller, BA","PresenterKey":"56984bef-ba8f-4024-9411-27453a16a8ad","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT265. Trastuzumab emtansine in patients (pts) with <i>HER2<\/i> mutation-positive <i>(HER2<\/i>mut<i>)<\/i> tumors: TAPISTRY study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trastuzumab emtansine in patients (pts) with <i>HER2<\/i> mutation-positive <i>(HER2<\/i>mut<i>)<\/i> tumors: TAPISTRY study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Immune checkpoint blockade,Surufatinib,High-grade advanced-neuroendocrine neoplasm,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>P. Zhang<\/b>, Y. Wang, J. Li, L. Shen, M. Lu; <br\/>Peking University Cancer Hospital & Institute, Beijing, China","CSlideId":"","ControlKey":"bbfcb2af-3da0-42ad-8f3a-9f37a2f04282","ControlNumber":"10532","DisclosureBlock":"&nbsp;<b>P. Zhang, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>L. Shen, <\/b> None..<br><b>M. Lu, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11587","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"23","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT266","PresenterBiography":null,"PresenterDisplayName":"Panpan Zhang, Dr PH","PresenterKey":"ae3eab52-d3d1-44c9-b833-bd021964db08","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT266. Initial efficacy of surufatinib plus sintilimab and IBI310 for patients with high-grade advanced-neuroendocrine neoplasm: A multicenter, single arm phase 2 study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Initial efficacy of surufatinib plus sintilimab and IBI310 for patients with high-grade advanced-neuroendocrine neoplasm: A multicenter, single arm phase 2 study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Precision medicine,Akt,Solid tumors,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Behl<\/b><sup>1<\/sup>, M. Rothe<sup>2<\/sup>, P. K. Mangat<sup>2<\/sup>, E. Garrett-Mayer<sup>2<\/sup>, N. Mackler<sup>3<\/sup>, H. L. Duvivier<sup>4<\/sup>, P. J. Gold<sup>5<\/sup>, S. R. Patel<sup>6<\/sup>, R. M. Duffy<sup>7<\/sup>, L. A. Mauro<sup>8<\/sup>, E. R. Ahn<sup>9<\/sup>, M. Bell<sup>10<\/sup>, C. J. Calfa<sup>11<\/sup>, J. L. Grem<sup>12<\/sup>, J. Rueter<sup>13<\/sup>, M. von Mehren<sup>14<\/sup>, G. N. Grantham<sup>2<\/sup>, A. Gregory<sup>2<\/sup>, D. C. Hinshaw<sup>2<\/sup>, S. Halabi<sup>15<\/sup>, R. L. Schilsky<sup>2<\/sup>; <br\/><sup>1<\/sup>Sutter Sacramento Medical Center, Sacramento, CA, <sup>2<\/sup>American Society of Clinical Oncology, Alexandria, VA, <sup>3<\/sup>Michigan Cancer Research Consortium, Ann Arbor, MI, <sup>4<\/sup>City of Hope Atlanta, Newnan, GA, <sup>5<\/sup>Swedish Cancer Institute, Seattle, WA, <sup>6<\/sup>Cancer Research Consortium of West Michigan, St. Joseph, MI, <sup>7<\/sup>Providence Cancer Institute, Portland, OR, <sup>8<\/sup>Inova Schar Cancer Institute, Fairfax, VA, <sup>9<\/sup>City of Hope Chicago, Zion, IL, <sup>10<\/sup>Sanford Health, Sioux Falls, SD, <sup>11<\/sup>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, <sup>12<\/sup>University of Nebraska Medical Center, Omaha, NE, <sup>13<\/sup>Jackson Laboratory-Maine Cancer Genomics Initiative, Bar Harbor, ME, <sup>14<\/sup>Fox Chase Cancer Center, Philadelphia, PA, <sup>15<\/sup>Duke University Medical Center, Durham, NC","CSlideId":"","ControlKey":"21b7425d-69c0-40a4-9747-aaf25fbd4e08","ControlNumber":"10683","DisclosureBlock":"<b>&nbsp;D. Behl, <\/b> <br><b>AstraZeneca<\/b> Other, Advisory Board, Speaker's bureau. <br><b>Takeda<\/b> Other, Advisory Board. <br><b>Bristol Myers Squibb<\/b> Other, Advisory Board. <br><b>Novartis<\/b> Other, Advisory Board.<br><b>M. Rothe, <\/b> None..<br><b>P. K. Mangat, <\/b> None..<br><b>E. Garrett-Mayer, <\/b> None..<br><b>N. Mackler, <\/b> None.&nbsp;<br><b>H. L. Duvivier, <\/b> <br><b>Guardant Health<\/b> Other, Speaker's bureau.<br><b>P. J. Gold, <\/b> None..<br><b>S. R. Patel, <\/b> None..<br><b>R. M. Duffy, <\/b> None.&nbsp;<br><b>L. A. Mauro, <\/b> <br><b>Eli Lilly and Company<\/b> Other, Speaker's bureau. <br><b>Biotheranostics<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board.<br><b>E. R. Ahn, <\/b> None..<br><b>M. Bell, <\/b> None..<br><b>C. J. Calfa, <\/b> None..<br><b>J. L. Grem, <\/b> None..<br><b>J. Rueter, <\/b> None.&nbsp;<br><b>M. von Mehren, <\/b> <br><b>Novartis<\/b> Grant\/Contract. <br><b>Deciphera<\/b> Grant\/Contract, serve on DSMB for study conducted by sponsor. <br><b>Theseus<\/b> Grant\/Contract. <br><b>Cogent<\/b> Grant\/Contract, Other, Scientific advisory board. <br><b>Boehringer Ingelheim<\/b> Other, Scientific advisory board. <br><b>Solarius<\/b> Grant\/Contract. <br><b>Sumito<\/b> Grant\/Contract. <br><b>ASCO<\/b> Grant\/Contract.<br><b>G. N. Grantham, <\/b> None.&nbsp;<br><b>A. Gregory, <\/b> <br><b>Biohaven Pharmaceuticals<\/b> Other, Employment of immediate family member\u000d\u000aStock holding by immediate family member. <br><b>Pfizer<\/b> Other, Employment of immediate family member\u000d\u000aStock holding by immediate family member.<br><b>D. C. Hinshaw, <\/b> None..<br><b>S. Halabi, <\/b> None.&nbsp;<br><b>R. L. Schilsky, <\/b> <br><b>Clarified Precision<\/b> Other, Leadership position. <br><b>Leap Therapeutics<\/b> Stock, Leadership position. <br><b>EQRx<\/b> Independent Contractor, Stock Option. <br><b>Cellworks<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Scandion Oncology<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Bryologyx<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Illumina<\/b> Independent Contractor, Consulting\/Advisory role. <br><b>Syapse<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>ZephyrAI<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>AstraZeneca, Bayer, Boehringer Ingelheim<\/b> Other, Research funding to ASCO in support of the TAPUR Study. <br><b>Bristol Myers Squibb, Eli Lilly and Company, Genentech<\/b> Other, Research funding to ASCO in support of the TAPUR Study. <br><b>Merck, Pfizer, Seagen, Taiho<\/b> Other, Research funding to ASCO in support of the TAPUR Study. <br><b>Aadi Bioscience<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Flatiron Health<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Toray Industries<\/b> Other, Honoraria for service on a study DSMB.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11588","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"24","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT267","PresenterBiography":null,"PresenterDisplayName":"Pam Mangat, MS","PresenterKey":"fc081116-f066-4da1-9c90-ecc97344c4d5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT267. Temsirolimus (T) in patients (pts) with solid tumors with <i>AKT1\/3 <\/i>amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Temsirolimus (T) in patients (pts) with solid tumors with <i>AKT1\/3 <\/i>amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Precision medicine,Cyclin D1,Solid tumors,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. Thota<\/b><sup>1<\/sup>, M. Rothe<sup>2<\/sup>, P. K. Mangat<sup>2<\/sup>, E. Garrett-Mayer<sup>2<\/sup>, T. Al Baghdadi<sup>3<\/sup>, E. Pisick<sup>4<\/sup>, O. B. Alese<sup>5<\/sup>, H. L. Duvivier<sup>6<\/sup>, A. S. Alva<sup>7<\/sup>, A. K. Ganti<sup>8<\/sup>, R. R. Induru<sup>9<\/sup>, A. M. Tsimberidou<sup>10<\/sup>, M. Akce<sup>11<\/sup>, N. Hafez<sup>12<\/sup>, E. Hobbs<sup>13<\/sup>, A. Riddle<sup>14<\/sup>, M. von Mehren<sup>15<\/sup>, G. N. Grantham<sup>2<\/sup>, A. Gregory<sup>2<\/sup>, D. C. Hinshaw<sup>2<\/sup>, S. Halabi<sup>16<\/sup>, R. L. Schilsky<sup>2<\/sup>; <br\/><sup>1<\/sup>Intermountain Healthcare, Murray, UT, <sup>2<\/sup>American Society of Clinical Oncology, Alexandria, VA, <sup>3<\/sup>Michigan Cancer Research Consortium, IHA Hematology Oncology, Ypsilanti, MI, <sup>4<\/sup>City of Hope Chicago, Zion, IL, <sup>5<\/sup>Winship Cancer Institute of Emory University, Atlanta, GA, <sup>6<\/sup>City of Hope Atlanta, Newnan, GA, <sup>7<\/sup>University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, MI, <sup>8<\/sup>University of Nebraska Medical Center and VA NWIHCS, Omaha, NE, <sup>9<\/sup>Levine Cancer Institute, Atrium Health, Charlotte, NC, <sup>10<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>11<\/sup>O’Neal Comprehensive Cancer Center, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, <sup>12<\/sup>The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, <sup>13<\/sup>Providence Cancer Institute, Portland, OR, <sup>14<\/sup>Cancer Research Consortium of West Michigan, Grand Rapids, MI, <sup>15<\/sup>Fox Chase Cancer Center, Philadelphia, PA, <sup>16<\/sup>Duke University Medical Center, Durham, NC","CSlideId":"","ControlKey":"2210eaa4-dd66-46e6-ac17-8d0b5586be2b","ControlNumber":"10435","DisclosureBlock":"&nbsp;<b>R. Thota, <\/b> None..<br><b>M. Rothe, <\/b> None..<br><b>P. K. Mangat, <\/b> None..<br><b>E. Garrett-Mayer, <\/b> None.&nbsp;<br><b>T. Al Baghdadi, <\/b> <br><b>Bristol Myers Squibb<\/b> Stock, Other, Advisory Board. <br><b>Cardinal Health<\/b> Travel, Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board. <br><b>Janssen<\/b> Other, Advisory Board. <br><b>Eli Lilly and Company<\/b> Other, Advisory Board. <br><b>Kite Pharma<\/b> Other, Advisory Board.<br><b>E. Pisick, <\/b> None.&nbsp;<br><b>O. B. Alese, <\/b> <br><b>Aadi Bioscience<\/b> Other, Advisory Board. <br><b>Taiho<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Other, Advisory Board. <br><b>Seagen<\/b> Other, Advisory Board. <br><b>Bristol Myers Squibb<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board. <br><b>Exelixis<\/b> Other, Advisory Board. <br><b>Takeda<\/b> Other, Advisory Board. <br><b>H. L. Duvivier, <\/b> <br><b>Guardant Health<\/b> Other, Speakers Bureau.<br><b>A. S. Alva, <\/b> None.&nbsp;<br><b>A. K. Ganti, <\/b> <br><b>Jazz Pharmaceuticals<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Independent Contractor. <br><b>Regeneron<\/b> Independent Contractor. <br><b>Sanofi Genzyme<\/b> Independent Contractor. <br><b>Cardinal Health<\/b> Independent Contractor. <br><b>Flagship Biosciences<\/b> Independent Contractor. <br><b>Beigene Ltd<\/b> Independent Contractor. <br><b>Mirati Therapeutics<\/b> Independent Contractor. <br><b>G1 Therapeutics<\/b> Independent Contractor. <br><b>Blueprint Medicines<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>YmAbs Therapeutics<\/b> Independent Contractor. <br><b>R. R. Induru, <\/b> <br><b>AstraZeneca<\/b> Independent Contractor, Other, Speakers bureau. <br><b>Bristol Myers Squibb<\/b> Other, Speakers bureau. <br><b>Regeneron<\/b> Other, Speakers bureau. <br><b>A. M. Tsimberidou, <\/b> <br><b>Agenus<\/b> Grant\/Contract. <br><b>Immatics<\/b> Grant\/Contract. <br><b>OBI Pharma<\/b> Grant\/Contract. <br><b>Novocure<\/b> Grant\/Contract. <br><b>Tempus<\/b> Grant\/Contract. <br><b>PICI<\/b> Grant\/Contract. <br><b>Tachyon Therapeutics<\/b> Grant\/Contract. <br><b>Tvardi Therapeutics<\/b> Grant\/Contract. <br><b>Orionis Biosciences<\/b> Grant\/Contract. <br><b>Avstera<\/b> Independent Contractor. <br><b>NEX-I<\/b> Independent Contractor. <br><b>Bioeclipse<\/b> Independent Contractor. <br><b>Bryet<\/b> Independent Contractor. <br><b>Macrogenics<\/b> Independent Contractor. <br><b>Vincerx<\/b> Independent Contractor. <br><b>M. Akce, <\/b> <br><b>Eisai<\/b> Other, Advisory Board. <br><b>Ipsen<\/b> Other, Advisory Board. <br><b>GSK<\/b> Other, Advisory Board. <br><b>Exelixis<\/b> Other, Advisory Board. <br><b>QED<\/b> Other, Advisory Board. <br><b>AstraZeneca<\/b> Other, Advisory Board. <br><b>Isifol Medical<\/b> Other, Advisory Board. <br><b>Genentech<\/b> Other, Advisory Board. <br><b>Incyte<\/b> Other, Advisory Board. <br><b>Taiho<\/b> Other, Advisory Board.<br><b>N. Hafez, <\/b> None..<br><b>E. Hobbs, <\/b> None..<br><b>A. Riddle, <\/b> None.&nbsp;<br><b>M. von Mehren, <\/b> <br><b>Novartis<\/b> Grant\/Contract. <br><b>Deciphera<\/b> Grant\/Contract, Other, serve on DSMB for study conducted by sponsor. <br><b>Theseus<\/b> Grant\/Contract. <br><b>Cogent<\/b> Grant\/Contract, Other, Scientific advisory board. <br><b>Boehringer Ingelheim<\/b> Other, Scientific advisory board. <br><b>Solarius<\/b> Grant\/Contract. <br><b>Sumito<\/b> Grant\/Contract. <br><b>ASCO<\/b> Grant\/Contract.<br><b>G. N. Grantham, <\/b> None.&nbsp;<br><b>A. Gregory, <\/b> <br><b>Biohaven Pharmaceuticals<\/b> Other, Employment of immediate family member\u000d\u000aStock holding by immediate family member. <br><b>Pfizer<\/b> Other, Employment of immediate family member\u000d\u000aStock holding by immediate family member.<br><b>D. C. Hinshaw, <\/b> None..<br><b>S. Halabi, <\/b> None.&nbsp;<br><b>R. L. Schilsky, <\/b> <br><b>Clarified Precision<\/b> Other, Leadership Position. <br><b>Leap Therapeutics<\/b> Stock, Other, Leadership Position. <br><b>EQRx<\/b> Independent Contractor, Stock Option. <br><b>Cellworks<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Scandion Oncology<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Bryologyx<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Illumina<\/b> Independent Contractor, Consulting\/Advisory role. <br><b>Syapse<\/b> Independent Contractor, Consulting\/Advisory role. <br><b>ZephyrAI<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>AstraZeneca, Bayer, Boehringer Ingelheim<\/b> Other, Research funding to ASCO in support of the TAPUR Study. <br><b>Bristol Myers Squibb, Genentech, Lilly<\/b> Other, Research funding to ASCO in support of the TAPUR Study. <br><b>Merck, Pfizer, Seagen, Taiho Oncology<\/b> Other, Research funding to ASCO in support of the TAPUR Study. <br><b>Flatiron Health<\/b> Independent Contractor, Other, Consulting\/Advisory role. <br><b>Aadi Biosciences<\/b> Independent Contractor, Consulting\/Advisory role. <br><b>Toray Industries<\/b> Other, Honoraria for service on a study DSMB.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11589","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"25","PosterboardNumber":"27","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT268","PresenterBiography":null,"PresenterDisplayName":"Pam Mangat, MS","PresenterKey":"fc081116-f066-4da1-9c90-ecc97344c4d5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT268. Palbociclib (P) in patients (pts) with solid tumors with <i>CCND1 <\/i>amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"616","SessionOnDemand":"False","SessionTitle":"Phase II Clinical Trials 2","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Palbociclib (P) in patients (pts) with solid tumors with <i>CCND1 <\/i>amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","Topics":null,"cSlideId":""}]